Welcome to your CDP Climate Change Questionnaire 2023

C0. Introduction

C0.1

(C0.1) Give a general description and introduction to your organization.

Important Stakeholder Disclaimer:

Some statements in this report are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe,""expect,""anticipate," "project" and similar expressions, and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors,"of AbbVie's 2022 Annual Report on Form 10- K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. Additionally, terms such as "ESG," "impact" and "sustainability" can be subjective in nature, and there is no representation or guarantee that these terms, as used in the response, will reflect the beliefs or values, policies, principles, frameworks or preferred practices of any particular investor or other third-party or reflect market trends. Any ESG, climate or impact goals, commitments, incentives and initiatives outlined in this response are, unless explicitly stated otherwise in this response, purely voluntary, are not binding on our business and/or management and do not constitute a guarantee, promise or commitment regarding actual or potential positive impacts or outcomes.

About AbbVie:

AbbVie's mission is to discover and deliver innovative medicines and products that solve serious health issues and enhance people's lives today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, and virology in addition to products and services across our aesthetics portfolio. Our state-of the-art research, development, and manufacturing centers across the world allow us to move the best ideas

forward faster and deliver transformative change. Our global headquarters is in North Chicago, IL, United States. We pride ourselves on a long tradition of strong corporate governance and financial controls, led by our board of directors. They play an active and vital role in overseeing our strategic direction and our performance against all objectives on behalf of our stakeholders. For more information about AbbVie, please visit us at www.abbvie.com.

AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. AbbVie includes four main business units which are Operations, Research & Development (R&D), Commercial, and Headquarters. AbbVie operates thirty-six significant Operations and R&D sites. AbbVie also operates a significant number of small Commercial affiliate offices around the globe.

As we respond to the concerns of our stakeholders, we will strive to find innovative solutions that are both good for business and good for the environment. We aim to ensure that our energy management practices and provisions are respectful of local needs and concerns. We also commit to using our energy management knowledge and experience to address broader energy issues as necessary and appropriate. We will seek to use company-wide policy, standards, and management systems to assure responsible energy management programs are implemented. Stakeholder engagement and collaborative problem-solving play a central role in the development and implementation of these programs.

We prioritize environmental sustainability within and beyond AbbVie to support our patients, people and planet. Our environmental sustainability strategy is focused on reducing our environmental footprint, growing sustainably through inspiring innovation, and engaging our workforce to steward sustainability.

C0.2

(C0.2) State the start and end date of the year for which you are reporting data and indicate whether you will be providing emissions data for past reporting years.

Reporting year

Start date

January 1, 2022

End date

December 31, 2022

Indicate if you are providing emissions data for past reporting years

No

C0.3

(C0.3) Select the countries/areas in which you operate.

Algeria
Argentina
Australia
Austria
Bahrain

Belarus
Belgium
Bosnia & Herzegovina
Brazil
Bulgaria
Canada
Chile
China
Colombia
Costa Rica
Croatia
Czechia
Denmark
Dominican Republic
Egypt
Estonia
Finland
France
Germany
Greece
Guatemala
Hong Kong SAR, China
Hungary
India
Ireland
Israel
Italy
Japan
Jordan
Kazakhstan
Kuwait
Latvia
Lebanon
Lithuania
Luxembourg
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal

Puerto Rico
Qatar
Republic of Korea
Romania
Russian Federation
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Switzerland
Taiwan, China
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom of Great Britain and Northern Ireland
United States of America
Uruguay
Viet Nam

C0.4

(C0.4) Select the currency used for all financial information disclosed throughout your response.

USD

C0.5

(C0.5) Select the option that describes the reporting boundary for which climate-related impacts on your business are being reported. Note that this option should align with your chosen approach for consolidating your GHG inventory.

Operational control

C0.8

(C0.8) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)?

Indicate whether you are able to provide a unique identifier for your organization	Provide your unique identifier
Yes, an ISIN code	US00287Y1091
Yes, a Ticker symbol	ABBV

C1. Governance

C1.1

(C1.1) Is there board-level oversight of climate-related issues within your organization?

Yes

C1.1a

(C1.1a) Identify the position(s) (do not include any names) of the individual(s) on the board with responsibility for climate-related issues.

Position of individual or committee	Responsibilities for climate-related issues
Board-level committee	AbbVie's Board of Directors and its Public Policy and Sustainability Committee provide oversight on matters related to climate-related risks and strategies, with annual updates from executive management on environmental strategy, action plans, objectives, and progress against established sustainability goals.

C1.1b

(C1.1b) Provide further details on the board's oversight of climate-related issues.

Frequency with which climate-related issues are a scheduled agenda item	Governance mechanisms into which climate-related issues are integrated	Please explain
Scheduled – some meetings	Overseeing and guiding employee incentives Reviewing and guiding strategy Overseeing the setting of corporate targets Reviewing and guiding the risk management process	AbbVie maintains an established governance process for oversight and management of our climate and environmental sustainability efforts. AbbVie's Public Policy and Sustainability Committee provide oversight on matters related to climate-related risks and strategies, with annual updates from executive management on environmental strategy, action plans, objectives, and progress against established sustainability goals. The Board of Directors also oversees the enterprise risk management review as well as Named Executive Officer (NEO) compensation with regards to ESG goals.

C1.1d

(C1.1d) Does your organization have at least one board member with competence on climate-related issues?

	Board member(s) have competence on climate-related issues	Criteria used to assess competence of board member(s) on climate-related issues
Row 1	Yes	There are currently four board members on the Abbvie Public Policy and Sustainability Committee. Board members are considered based on a range of criteria including broad-based business knowledge and relationships, prominence and excellent reputations in their primary fields of endeavor, as well as a global business perspective and commitment to good corporate citizenship, diversity, and ability to commit sufficient time and attention to the activities of the board. They must have demonstrated experience and ability that is relevant to the board's oversight role with respect to AbbVie's business and affairs. AbbVie's 2023 Proxy Statement lists each member of the board, their business experience, and their key contributions to the board. One member of the Public Policy and Sustainability committee has experience in risk management as well as climate change. The other three members of the Public Policy and Sustainability committee have listed experience in ESG, environmental, and sustainability matters.

C1.2

(C1.2) Provide the highest management-level position(s) or committee(s) with responsibility for climate-related issues.

Position or committee

Other C-Suite Officer, please specify

Executive Vice President (EVP) Operations

Climate-related responsibilities of this position

Managing annual budgets for climate mitigation activities
Developing a climate transition plan
Implementing a climate transition plan
Setting climate-related corporate targets
Monitoring progress against climate-related corporate targets
Assessing climate-related risks and opportunities
Managing climate-related risks and opportunities

Coverage of responsibilities

Reporting line

CEO reporting line

Frequency of reporting to the board on climate-related issues via this reporting line

Annually

Please explain

AbbVie's Executive Vice President (EVP) of Operations has direct responsibility for climate-related issues. The EVP of Operations is an AbbVie C-suite corporate officer, who reports directly to the CEO, and is responsible for AbbVie's Operations organization, including the Global Environmental, Health & Safety organization. The Executive Vice President of Operations presents to the Public Policy and Sustainability committee on environmental and climate related issues at periodic meetings. The update to the board includes environmental strategy, action plans, objectives, and progress against the established environmental sustainability goals for AbbVie.

C1.3

(C1.3) Do you provide incentives for the management of climate-related issues, including the attainment of targets?

	Provide incentives for the management of climate-related issues	Comment
Row 1	Yes	AbbVie's Named Executive Officers (NEOs) take a formal goal aligned to driving AbbVie's environmental, social, and governance (ESG) framework. AbbVie's NEO's include our CEO and five executives that report directly to the CEO. The ESG goal was weighted 10% within the short-term incentive program for each NEO. Progress against AbbVie GHG reduction target was listed as a key achievement for this incentive program for 2022.

C1.3a

(C1.3a) Provide further details on the incentives provided for the management of climate-related issues (do not include the names of individuals).

Entitled to incentive

Chief Executive Officer (CEO)

Type of incentive

Monetary reward

Incentive(s)

Bonus - % of salary

Performance indicator(s)

Progress towards a climate-related target

Incentive plan(s) this incentive is linked to

Short-Term Incentive Plan

Further details of incentive(s)

AbbVie's Named Executive Officers (NEOs) take a formal goal aligned to driving AbbVie's environmental, social, and governance (ESG) framework. AbbVie's NEO's include our CEO . The ESG goal was weighted 10% within the short-term incentive program for each NEO. Progress against AbbVie GHG reduction target was listed as a key achievement for this incentive program for 2022.

Explain how this incentive contributes to the implementation of your organization's climate commitments and/or climate transition plan

Our NEOs (inclusive of our CEO) have a formal goal aligned to driving AbbVie's ESG framework. The ESG Goal was weighted at 10% within the short-term incentive program for each NEO. This short-term incentive plan is linked to AbbVie's progress towards climate-related targets of reducing our absolute scope 1 and 2 GHG emissions by 42% by 2030 and achieving 100% purchased renewable electricity by 2030.

Entitled to incentive

Other C-Suite Officer

Type of incentive

Monetary reward

Incentive(s)

Bonus - % of salary

Performance indicator(s)

Progress towards a climate-related target

Incentive plan(s) this incentive is linked to

Short-Term Incentive Plan

Further details of incentive(s)

AbbVie's Named Executive Officers (NEOs) take a formal goal aligned to driving AbbVie's environmental, social, and governance (ESG) framework. AbbVie's Executive Vice President (EVP) of Operations is a NEO that report directly to the CEO. The ESG goal was weighted 10% within the short-term incentive program for each NEO. Progress against AbbVie GHG reduction target was listed as a key achievement for this incentive program for 2022.

Explain how this incentive contributes to the implementation of your organization's climate commitments and/or climate transition plan

Our NEOs have a formal goal aligned to driving AbbVie's ESG framework. The ESG Goal was weighted at 10% within the short-term incentive program for each NEO. This short-term incentive plan is linked to AbbVie's progress towards climate-related targets of reducing our absolute scope 1 and 2 GHG emissions by 42% by 2030 and achieving 100% purchased renewable electricity by 2030.

Entitled to incentive

Energy manager

Type of incentive

Monetary reward

Incentive(s)

Bonus - % of salary
Salary increase

Performance indicator(s)

Progress towards a climate-related target
Implementation of an emissions reduction initiative
Implementation of employee awareness campaign or training program on climate-related issues

Incentive plan(s) this incentive is linked to

Both Short-Term and Long-Term Incentive Plan

Further details of incentive(s)

Within the AbbVie Global EHS organization, the Director for Global Energy Management and the Program Manager for Energy Management carry annual goals around progress towards our climate related targets, implementation of energy efficiency and decarbonization initiatives, and employee engagement on energy and GHG topics. Achievement of these goals influence the annual bonus and salary increases that are awarded, as well as the amount of Long Term Incentives that are awarded to these employees.

Explain how this incentive contributes to the implementation of your organization's climate commitments and/or climate transition plan

Our Energy Managers have a formal goal aligned to driving AbbVie's framework. The ESG goal for this role is both part of a short term and long-term incentive plan linked to AbbVie's progress towards our climate-related target reducing our absolute scope 1 and 2 GHG emissions by 42% by 2030, implementation of an emissions reduction initiatives, and implementation of employee awareness campaigns or training programs on climate-related issues.

Entitled to incentive

Procurement manager

Type of incentive

Monetary reward

Incentive(s)

Bonus - % of salary
Salary increase

Performance indicator(s)

Progress towards a climate-related target
Implementation of an emissions reduction initiative
Increased engagement with suppliers on climate-related issues

Incentive plan(s) this incentive is linked to

Both Short-Term and Long-Term Incentive Plan

Further details of incentive(s)

Within the AbbVie Global Purchasing and Supplier Management organization, the Manager for Supplier Sustainability carries annual goals around progress towards our climate related targets, implementation of Scope 3 reduction initiatives, and engagement with suppliers on Scope 3 emissions. Achievement of these goals influence the annual bonus and salary increases that are awarded, as well as the amount of Long Term Incentives that are awarded to these employees.

Explain how this incentive contributes to the implementation of your organization's climate commitments and/or climate transition plan

Our Procurement Managers have a formal goal aligned to driving AbbVie's framework. The ESG goal for this role is both part of a short term and long term incentive plan linked to AbbVie's progress towards a climate-related target reducing our absolute scope 1 and 2 GHG emissions by 42% by 2030, implementation of an emissions reduction initiatives, and increased engagement with suppliers on climate-related issues to reach our goal of 79.1% of suppliers (by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution) will have science-based targets by 2027.

C2. Risks and opportunities

C2.1

(C2.1) Does your organization have a process for identifying, assessing, and responding to climate-related risks and opportunities?

Yes

C2.1a

(C2.1a) How does your organization define short-, medium- and long-term time horizons?

	From (years)	To (years)	Comment
Short-term	0	5	AbbVie has identified the short-term time horizon as 5 years (2023 through 2027).
Medium-term	5	15	AbbVie has identified the medium-term time horizon as 10 years beyond that (2028 through 2037).

Long-term	15	30	AbbVie has identified the long-term time horizon as 15 years beyond that (2038 through 2052).

C2.1b

(C2.1b) How does your organization define substantive financial or strategic impact on your business?

Substantive risks for the company are set at a much higher financial and strategic impact threshold. Substantive strategic impacts would include things that could negatively impact our product pipeline, manufacturing capabilities, regulatory compliance, employee health & safety, and our reputation. Climate risks would generally be considered to have a substantive financial impact when greater than $100 million on an annual basis, though such an impact should not be equated to or taken as a representation about “materiality” under the US federal securities laws or any similar legal or regulatory regime globally. Climate risks with strategic impact to the business would also be considered substantive.

C2.2

(C2.2) Describe your process(es) for identifying, assessing and responding to climate-related risks and opportunities.

Value chain stage(s) covered

Direct operations
Upstream
Downstream

Risk management process

Integrated into multi-disciplinary company-wide risk management process

Frequency of assessment

Annually

Time horizon(s) covered

Short-term
Medium-term
Long-term

Description of process

AbbVie has a well-established Risk Management program as well as a Crisis Preparedness and Business Continuity planning program. These two programs cover all of AbbVie’s operations globally. The three key steps in both programs are to
(1) analyze the business for sources of risk
(2) assess the risks
(3) develop strategies to address the risks.

Elements of prevention, preparedness, response, recovery, and sustainability are

incorporated into the programs. Climate-related risks are included within the risks that are addressed by these programs. AbbVie uses a Global Risk Profile approach to evaluate and prioritize a variety of risks geographically. We take an “All Hazards” approach in our evaluations, identifying risks in the following categories:
(1) Natural Hazards (including climate-related risks)
(2) Security / Political / Social
(3) Financial and Investment

We also consider attendant risks to regulatory compliance, employee health & safety, and reputation with input from Public Affairs, Government Affairs, Regulatory Affairs, Legal, and EHS. The Risk Management function leads the annual process of identifying risks. Short-term, Medium-term, and Long-term are considered within this process. The Risk Management function reviews the progress of risk mitigation plans with the Executive Leadership Team on a quarterly basis.

AbbVie's Global EHS organization leads specific Climate Risk assessment activities on a periodic basis. The scope of physical risk assessments includes evaluating AbbVie sites around the world including manufacturing, R&D, and warehouse locations, along with selected commercial offices. We use qualitative and quantitative climate-related scenario analyses to assess climate-related physical risks. In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. The analysis looked at how physical hazards such as water stress, flooding, heatwave, cold wave, hurricane, wildfire and coastal flood risk might change along three climate change scenarios: High Warming Scenario (RCP 8.5), Moderate Warming Scenario (RCP 4.5), and High Climate Mitigation Scenario (RCP 2.6). These scenarios are based on the IPCC’s Representative Concentration Pathways (RCP) and are aligned with the TCFD technical guidelines (FSB, 2017). We assessed the impacts of these physical hazards across time horizons to look beyond traditional business planning cycles; 2025, 2030 and 2050. The scope of the analysis encompassed 100 global AbbVie sites and locations including all manufacturing, R&D, warehouse locations, along with selected commercial affiliate offices. It also included the top 35 locations of our critical upstream suppliers, the top 20 locations for our downstream third-party logistic warehouses and all 9 of our global third-party data centers. This physical risk assessment will be repeated every five years or if a significant change occurs within our operational footprint. AbbVie has also initiated a Climate Risk assessment for transition risks focusing primarily on regulatory transition risk. This assessment is ongoing and is expected to be complete in Q3 of 2022.

AbbVie periodically conducts more general level assessments on the physical and transition risks of climate change and includes our upstream operations in addition to our downstream operations and clients. This includes an annual analysis of water risk across our manufacturing and research sites. We use the WRI Aqueduct tool to assess 100% of our direct and indirect water-related risks through 2030 and assess water-related risks of key suppliers globally.

We anticipate that climate change may have varying levels of impact on our business across the short-, medium-, and long-term. AbbVie seeks to understand and anticipate

these impacts to ensure we sustain the discovery and development of innovative medicines for both current and future patients. This effort involves evaluating our operations and supply chains for potential disruptions in connection with climate change and implementing contingency plans or advance preparedness. We invest in business continuity efforts that contribute to mitigating the potential for risk of loss and promote business continuity in the event a climate-related risk materializes. AbbVie's Crisis Preparedness and Business Continuity group develops and maintains the needed infrastructure, procedures, and practices that enable us to mitigate risks and respond to crisis events that may adversely impact our business, employees or surrounding communities. Each operating and commercial division have documented business continuity plans that address key products and operations. The overall Crisis Preparedness and Business Continuity plan is reviewed at the executive level on an annual basis, and all business continuity plans are reviewed on a biennial basis. AbbVie also invests in the assurance of supply activities including selecting redundant suppliers for raw materials, manufacturing products at multiple locations globally, and redundant shipping supply chains to deliver our products. The combination of our crisis preparedness activities and our assurance of supply activities is the way that AbbVie seeks to effectively address increasing climate risk.

C2.2a

(C2.2a) Which risk types are considered in your organization's climate-related risk assessments?

	Relevance & inclusion	Please explain
Current regulation	Relevant, always included	AbbVie is a global bio-pharmaceutical company that develops new medicines, produces and manufactures those medicines, and markets them globally. Bio-pharmaceuticals is a highly regulated industry and current regulation is always relevant and considered in our risk process. In addition, our upstream suppliers and downstream distribution partners are subject to the same regulations. Increased capital expenditure and increased operational costs are included in this risk. As an example, AbbVie has manufacturing sites in eleven different countries around the world (United States, Ireland, Germany, Italy, France, Belgium, Costa Rica, Brazil, Israel, Singapore, and Puerto Rico). Our operations in Ireland and Germany are subject to the EU ETS carbon cap and trade system, through which we incur increased costs. We monitor and manage these costs to ensure financial stability. AbbVie is also subject to existing regulations around refrigerants. The phase down of refrigerants with high Global Warming Potential's will require AbbVie to invest in refrigeration equipment upgrades and replacements globally.
Emerging regulation	Relevant, always included	New climate-related regulations are being proposed and enacted around the world. Our business and those of our upstream and downstream suppliers and partners are subject to the risk associated

		with these emerging climate-related regulations. Increased capital expenditure and increased operational costs are included in this risk. We continually monitor and assess the emerging regulations in all countries where we do business, to identify where we may incur increased cost (e.g., new or rising carbon taxes); new activities (e.g., new procedural or reporting requirements) or other risks (e.g., new minimum standards on air and water). AbbVie has seen an increased cost of carbon in many of these countries. For example, our operations in Ireland are subject to the Irish carbon tax. The current carbon tax is 37 EUR/Metric Ton, and is expected to rise to 100 EUR/Metric Ton. Singapore has also enacted a carbon tax. In all these cases, AbbVie is looking at ways to improve our energy efficiency to bring our Scope 1 and 2 emissions down which will then reduce the financial impact of the increasing cost of carbon.
Technology	Relevant, always included	AbbVie continually assesses changes in technology and the impact to our products and business. In general, AbbVie believes changes in technology will have a positive impact on our ability to decrease our carbon footprint. AbbVie is likely to invest in technology innovations rather than identify them as a risk. For example, in 2022 AbbVie made a significant investment in replacing utilities equipment (boilers, chillers, air compressors, HVAC, etc) at our global sites. All the replaced equipment utilizes high efficiency design to reduce the fuel or electricity usage of the equipment.
Legal	Relevant, always included	AbbVie continually assesses legal changes in all countries where we do business. The pharmaceutical industry is a relatively low carbon intensity sector when compared to energy production or raw material production. AbbVie's efforts to reduce our carbon footprint have been voluntary. Climate-related litigation claims have not been deemed to pose a risk to our business, and to date no claims have been raised.
Market	Relevant, always included	AbbVie continually assesses market changes in all countries where we do business. In some markets, we have seen increased requests for environmental sustainability progress and the environmental impact of our products. AbbVie has participated in tender offers in European countries where environmental information is consistently requested and considered in procurement decisions. Our efforts in environmental stewardship have improved our position and competitiveness within these tender offers.
Reputation	Relevant, always included	AbbVie's ESG Framework is built around three foundational pillars that align with our enterprise goals and principles. These have been developed based on an analysis of our material issues, considering the topics of most interest and relevance to our company and our stakeholders—including our patients, patient organizations, employees, investors, regulators and government, payers and providers, suppliers and nonprofit partners.

		Collaboration with stakeholders is critical to our success. We strive to create value by building engaging, long-term relationships with each of our partners and stakeholders. Through these relationships, we engage in regular dialogue to understand evolving needs, interests and expectations of AbbVie. From these interactions, we develop our understanding of meaningful issues and identify additional opportunities to improve and make an impact. We prioritize Environmental Sustainability within and beyond AbbVie to support our patients, people and the planet. We are focused on reducing our environmental footprint, growing sustainability through inspiring innovation and engaging our workforce to steward the same.
Acute physical	Relevant, always included	Acute physical risk is considered a relevant operational, strategic, and financial risk. AbbVie has identified the increased severity of climate change-related weather events as a potential near-term risk to our operations and supply chains. Disruption to our supply chains can have a significant impact to the availability of medicines for patients. Reduced revenue is included in this risk. AbbVie has manufacturing sites in Puerto Rico. This is an area that has been identified as being at a higher risk for more severe storms. Significant efforts have been made for contingency planning for these manufacturing sites. In 2019, AbbVie completed an investment to replace the electrical co-generation system and electrical infrastructure at our primary site in Puerto Rico. This investment is intended to increase the resiliency of the site during severe weather events.
Chronic physical	Relevant, always included	Chronic physical risk is considered a relevant operational, strategic, and financial risk. AbbVie has identified increasing global temperatures, increased levels of water stress, and sea level rise as potential risks to our operations. In the medium term, water stress at our global sites and our upstream supplier sites has been identified as an emerging risk. AbbVie has operations at multiple sites where water stress is increasing, and there is increased risk that water demands may not be met resulting in limitations on freshwater resources. As a result, in the medium term, there is a risk that clean water supplies may become more limited. In the long term, coastal sea level rise has been identified as a risk. AbbVie operates a manufacturing site in Singapore and an R&D site in South San Francisco that are in low-lying coastal areas. Although neither facility is in an area where there is direct physical risk to the site, coastal flooding may have an impact on critical public infrastructure, in the area which has the potential for business disruption .

C2.3

(C2.3) Have you identified any inherent climate-related risks with the potential to have a substantive financial or strategic impact on your business?

Yes

C2.3a

(C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your business.

Identifier

Risk 1

Where in the value chain does the risk driver occur?

Direct operations

Risk type & Primary climate-related risk driver

Acute physical

Cyclone, hurricane, typhoon

Primary potential financial impact

Decreased revenues due to reduced production capacity

Company-specific description

In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Increased intensity of Tropical Storms (hurricanes/typhoons) were identified as a high risk at our manufacturing facilities in Puerto Rico which are at risk of damage from strong storms. In addition, we have global supply chains and distribution routes in at-risk regions. We have identified one of our greatest climate-related risk to be business interruption during extreme weather and the related aftermath.

Time horizon

Short-term

Likelihood

Virtually certain

Magnitude of impact

High

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

No explanation.

Cost of response to risk

Description of response and explanation of cost calculation

AbbVie operates a facility in Puerto Rico where product components are manufactured. Due to its location in the Caribbean, this site is at an increased risk of hurricane. To promote business continuity of operations, AbbVie has invested heavily in redundant manufacturing capabilities in Massachusetts and Singapore which would allow for a continuity of supply in the event the Puerto Rico location is unable to function.
Investments have been and continue to be made to proactively address the resiliency of our facilities, such as reinforcing the physical infrastructure and providing backup on-site power supply. This is aligned to our Crisis Preparedness strategy. These measures helped to minimize the business impact of the 2017 hurricanes in Puerto Rico, as our facilities in Puerto Rico had been designed to withstand category 5 Hurricanes, we have on-site power generation, an on-site supply of water, and a well-developed crisis management plan. For business activities occurring in the highest risk areas, redundant manufacturing capacity, supply chains and shipping routes have been established in lower risk locations. This is aligned to our Assurance of Supply strategy.
We realize that weather events may not only impact AbbVie but also the partners we rely on within AbbVie's supply chain. To mitigate climate-related disruptions to AbbVie's supply chain, AbbVie works with its supply chain partners to ensure they have robust continuity plans and makes investments itself in assurance of supply activities. This investment includes, but is not limited to, obtaining redundant suppliers for raw materials, manufacturing products at multiple locations globally, and using redundant shipping supply chains to deliver our products
It is difficult to exactly quantify the cost of management for this climate-specific risk, because many of these initiatives also address other risks as part of our overall Crisis Preparedness and Assurance of Supply strategy. No cost of the response to the risk is provided.

Comment

Although this risk has a high likelihood and a high impact, our Crisis Preparedness strategy and Assurance of Supply strategy have put us in a position to minimize the impact, thus making a scenario that approaches a significant financial impact unlikely.

Identifier

Risk 2

Where in the value chain does the risk driver occur?

Direct operations

Risk type & Primary climate-related risk driver

Acute physical
Wildfire

Primary potential financial impact

Decreased revenues due to reduced production capacity

Company-specific description

In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Wildfires were identified as a high risk at most of our operations in California. Although none of the sites are in locations where we would expect direct physical risk to the site, the level of business disruption from power outages and smoke as well as disruption to personnel may be significant. In addition, we have suppliers in high-risk regions. We have identified one of our greatest near term climate-related risks to be business interruption associated with wildfires.

Time horizon

Short-term

Likelihood

Virtually certain

Magnitude of impact

High

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

No explanation.

Cost of response to risk

Description of response and explanation of cost calculation

AbbVie operates multiple facilities in California where product components are manufactured and R&D is conducted. Due to their locations in California, the sites are at an increased risk for wildfire. To promote business continuity of operations, AbbVie has invested heavily in redundant manufacturing and R&D capabilities around the globe which would allow for a continuity of supply in the event one of the California locations is unable to function.

Investments have been and continue to be made to proactively address the resiliency of our facilities, such as providing backup on-site power supply. This is aligned to our Crisis Preparedness strategy. These measures helped to minimize the business impact of the 2020 and 2021 wildfires in California, as our facilities had been designed with emergency power generation and well-developed crisis management plans were in place. For business activities occurring in the highest risk areas, redundant manufacturing capacity, supply chains and shipping routes have been established in

lower risk locations. This is aligned to our Assurance of Supply strategy.
We realize that wildfire events may not only impact AbbVie but also the partners we rely on within AbbVie's supply chain. To mitigate climate-related disruptions to AbbVie's supply chain, AbbVie works with its supply chain partners to ensure they have continuity plans and makes investments itself in assurance of supply activities. This investment includes, but is not limited to, obtaining redundant suppliers for raw materials, manufacturing products at multiple locations globally, and using redundant shipping supply chains to deliver our products
It is difficult to exactly quantify the cost of management for this climate-specific risk, because many of these initiatives also address other risks as part of our overall Crisis Preparedness and Assurance of Supply strategy.

Comment

Although this risk has a high likelihood and a high impact, our Crisis Preparedness strategy and Assurance of Supply strategy have put us in a position to minimize the impact, thus making a scenario that approaches a significant financial impact unlikely.

Identifier

Risk 3

Where in the value chain does the risk driver occur?

Direct operations

Risk type & Primary climate-related risk driver

Chronic physical
Water scarcity

Primary potential financial impact

Decreased revenues due to reduced production capacity

Company-specific description

In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Water Stress was identified as a growing risk across our operational sites. Both climate change and population density will have a negative impact on the water supplies in the areas where we operate causing water supplies to become more scarce and limited. There will be a corresponding increase in the cost of water, as well as potential limitations on the amount of water that can be withdrawn. We currently have a limited number of sites in high water stress areas such as our Campoverde, Italy site, but we expect that to increase to over 20 operational sites in the future. This includes our Tuas, Singapore site, all of our California sites, and others around the globe.
AbbVie has suppliers in areas where water stress is a growing risk issue, and lack of access to enough clean water is a growing risk.

Time horizon

Medium-term

Likelihood

Very likely

Magnitude of impact

High

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

No explanation.

Cost of response to risk

Description of response and explanation of cost calculation

AbbVie considers decreasing our water usage and implementing water efficiency projects to be the most effective method to manage this risk. AbbVie has established an absolute water reduction goal for 2025 and 2035 compared to our 2015 baseline. AbbVie has a global Subject Matter Expert who concentrates on clean utilities including Water treatment, Purified Water, and Water for Injection systems. Many of AbbVie's manufacturing sites are ISO 14001 certified. AbbVie is managing the water risk and the cost impact by driving water reductions and implementing water management programs at our highest water stress sites. AbbVie had a centralized environmental capital budget of $1,100,000 in 2020. This capital was used to fund multiple water efficiency projects at our global manufacturing sites. These funds are earmarked to help address these risks as well as other environmental related risks. The cost of the ISO 14001 program is estimated at $250,000 per year.

Comment

Although this risk has a high likelihood and a high impact, our Assurance of Supply strategy and our Water Conservation efforts have put us in a position to minimize the impact, thus making a scenario that approaches a significant financial impact unlikely.

Identifier

Risk 4

Where in the value chain does the risk driver occur?

Direct operations

Risk type & Primary climate-related risk driver

Chronic physical

Sea level rise

Primary potential financial impact

Increased capital expenditures

Company-specific description

In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. Costal sea level rise was identified as a long-term risk for our Tuas, Singapore manufacturing site and our South San Francisco, CA research and development site. Although neither facility is in an area where there is direct physical risk to the site, coastal flooding may have significant impact to critical public infrastructure in the area which has the potential to impact the site's ability to operate efficiently.

Time horizon

Long-term

Likelihood

More likely than not

Magnitude of impact

High

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

No explanation.

Cost of response to risk

Description of response and explanation of cost calculation

AbbVie continually evaluates our business strategy and how our global footprint of facilities contributes to that strategy. AbbVie has implemented measures to assess the risk of operating in various locations across the globe, and this consideration now includes climate risk. The government in Singapore and South San Francisco both acknowledge that increased levels of coastal sea level rise pose a risk to these areas and both areas have published plans to combat the issue. AbbVie will continue to monitor this long-term risk for the potential of negative impacts to our operations. Due the long-term nature and uncertainty of this risk, there is no estimated cost for responding to this risk at this time.

Comment

No comment.

Identifier

Risk 5

Where in the value chain does the risk driver occur?

Direct operations

Risk type & Primary climate-related risk driver

Emerging regulation

Carbon pricing mechanisms

Primary potential financial impact

Increased indirect (operating) costs

Company-specific description

The cost of carbon has been identified as a growing transition risk for our business. AbbVie participates in the EU Emissions Trading System (ETS) at our Ludwigshafen, Germany site and our Westport, Ireland site. AbbVie is subject to carbon taxes at sites in Ireland and Singapore. The cost of carbon attributes as well as carbon taxes has increased significantly in the last 4 years. This has increased both the cost of fuel and electricity at these sites. In addition, there has been increased discussion of enacting legislation/regulation that could increase the cost of carbon in the United States.

Time horizon

Medium-term

Likelihood

Likely

Magnitude of impact

High

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

No explanation.

Cost of response to risk

Description of response and explanation of cost calculation

AbbVie considers decreasing our carbon emissions and implementing energy efficiency projects to be the most effective method to manage costs associated with carbon regulation. AbbVie has established an absolute carbon reduction goal, and a goal to increase the purchase of renewable electricity. AbbVie has a Global Energy Community of Practice led by the Director of Global Energy Management. This team meets monthly and works to support the Global AbbVie sites with energy management and energy efficiency practices. Twelve of AbbVie's manufacturing sites are ISO 50001 certified. AbbVie is managing the regulatory risk and the cost impact by driving energy reductions and implementing energy management programs at our most energy intensive sites. AbbVie has established centralized energy efficiency and decarbonization capital budgets of $11,800,000 annually. This capital fund was used to fund energy efficiency and decarbonization projects at our global manufacturing sites. These funds are earmarked to help address these risks as well as other energy-related risks. The cost of the ISO 50001 program is estimated at $250,000.

Comment

No comment.

C2.4

(C2.4) Have you identified any climate-related opportunities with the potential to have a substantive financial or strategic impact on your business?

Yes

C2.4a

(C2.4a) Provide details of opportunities identified with the potential to have a substantive financial or strategic impact on your business.

Identifier

Opp1

Where in the value chain does the opportunity occur?

Direct operations

Opportunity type

Resource efficiency

Primary climate-related opportunity driver

Use of more efficient production and distribution processes

Primary potential financial impact

Reduced direct costs

Company-specific description

There is the opportunity for reduced operating costs that result from our energy efficiency strategy and initiatives. This applies to all of our global Operations, R&D, and Commercial sites. This effort is most notable at our Barceloneta, Puerto Rico site where our Scope 1 emissions by facility are the highest. AbbVie self-generates electricity at this site via cogeneration so almost all GHG emissions from the site are Scope 1 emissions. Fuel procurement for this location is a significant cost due to the fact that 100% of the LNG fuel has to be imported to the island.

Time horizon

Short-term

Likelihood

Virtually certain

Magnitude of impact

Low

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

No explanation.

Cost to realize opportunity

Strategy to realize opportunity and explanation of cost calculation

The primary strategy to realize this opportunity is to identify the best energy efficiency projects that have the greatest return on investment. AbbVie has a Global Energy Community of Practice led by the Director of Global Energy Management. This team meets monthly and works to support the Global AbbVie sites with energy management and energy efficiency practices. Twelve of AbbVie's manufacturing sites are ISO 50001 certified. AbbVie has found that implementing the ISO 50001 program at our sites is a "best in class" practice for identifying energy efficiency and savings opportunities. The estimated cost of management for the ISO 50001 program is $250,000 per year. AbbVie has established centralized energy efficiency and decarbonization capital budgets. This capital fund was used to fund energy efficiency and decarbonization projects at our global manufacturing sites. Sixteen total projects were funded, and all of the projects are either complete or in the implementation phase.

Comment

No comment.

Identifier

Opp2

Where in the value chain does the opportunity occur?

Direct operations

Opportunity type

Energy source

Primary climate-related opportunity driver

Use of new technologies

Primary potential financial impact

Reduced direct costs

Company-specific description

Energy Efficiency Technology – There is the opportunity for adopting new technology which will increase our energy efficiency and reduce our energy use and GHG emissions. This applies to all of our global Operations, R&D, and Commercial sites. This effort is most notable at our North Chicago manufacturing site, where we have implemented continuous HVAC monitoring software. The intention of the technology is to improve the overall maintenance program for the HVAC system, and we have found that by responding to HVAC issues in a more timely manner we have also realized decreased energy costs at the site. The total annual energy savings in the first year were equal to the cost of deploying the system.

Time horizon

Short-term

Likelihood

Likely

Magnitude of impact

Low

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

No explanation.

Cost to realize opportunity

Strategy to realize opportunity and explanation of cost calculation

The primary strategy to realize this opportunity is to identify new technology that increases the energy efficiency of our Operations, R&D, and Commercial sites. AbbVie has a Global Energy Community of Practice led by the Director of Global Energy Management. This team meets monthly and works to support the Global AbbVie sites with energy management and energy efficiency practices. Twelve of AbbVie's manufacturing sites are ISO 50001 certified. AbbVie has found that implementing the ISO 50001 program at our sites is a "best in class" practice for identifying energy efficiency and savings opportunities. The estimated cost of management for the ISO 50001 program is $250,000 per year.

AbbVie has implemented continuous HVAC monitoring software at one of our manufacturing sites. The intention of the technology is to improve the overall maintenance program for the HVAC system, and we have found that by responding to HVAC issues in a more timely manner we have also realized decreased energy costs at the site. The total annual energy savings in the first year were equal to the cost of deploying the system.

Comment

No comment.

Identifier

Opp3

Where in the value chain does the opportunity occur?

Direct operations

Opportunity type

Products and services

Primary climate-related opportunity driver

Development and/or expansion of low emission goods and services

Primary potential financial impact

Increased revenues resulting from increased demand for products and services

Company-specific description

Improved competitive advantage - There is the opportunity for improved competitive advantage in the marketplace.

Time horizon

Long-term

Likelihood

More likely than not

Magnitude of impact

Medium

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

No explanation.

Cost to realize opportunity

Strategy to realize opportunity and explanation of cost calculation

AbbVie continually assesses market changes in all countries where we do business. In some markets, we have seen increased requests for environmental sustainability progress and the environmental impact of our products. AbbVie has participated in tender offers in European countries where environmental information is consistently requested and considered within the tender offer decision process. Our efforts in environmental stewardship have improved our position and competitiveness within these tender offers. Over the long term this is anticipated to become a larger factor in the decision criteria of tender offers.

Comment

No comment.

C3. Business Strategy

C3.1

(C3.1) Does your organization's strategy include a climate transition plan that aligns with a 1.5°C world?

Row 1

Climate transition plan

No, but our strategy has been influenced by climate-related risks and opportunities, and we are developing a climate transition plan within two years

Explain why your organization does not have a climate transition plan that aligns with a 1.5°C world and any plans to develop one in the future

In 2022, AbbVie set a near-term 1.5 °C Science Based Target. This target was validated by SBTi in May of 2023. AbbVie is in process of developing & publishing a public written transition plan that details our pathway to achieving that target.

C3.2

(C3.2) Does your organization use climate-related scenario analysis to inform its strategy?

	Use of climate-related scenario analysis to inform strategy
Row 1	Yes, qualitative and quantitative

C3.2a

(C3.2a) Provide details of your organization's use of climate-related scenario analysis.

Climate-related scenario	Scenario analysis coverage	Temperature alignment of scenario	Parameters, assumptions, analytical choices
Physical climate scenarios RCP 8.5	Company-wide		In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. The analysis looked at on how physical hazards such as water stress, flooding, heatwave, cold wave, hurricane, wildfire and coastal flood risk might change along three climate change scenarios High Warming Scenario (RCP 8.5), Moderate Warming Scenario (RCP 4.5), and High Climate Mitigation Scenario (RCP 2.6). These scenarios are based on the IPCC's Representative Concentration Pathways (RCP) and are aligned with the TCFD technical guidelines (FSB, 2017). We assessed the impacts of these physical hazards across time horizons to look beyond traditional business planning cycles; 2025, 2030 and 2050.
Physical climate scenarios RCP 4.5	Company-wide		In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. The analysis looked at on how physical hazards such as water stress, flooding, heatwave, cold wave, hurricane, wildfire and coastal flood risk might change along three climate change scenarios High Warming Scenario (RCP 8.5), Moderate Warming Scenario (RCP 4.5), and High Climate Mitigation Scenario (RCP 2.6). These scenarios are based on the IPCC's Representative Concentration Pathways (RCP) and are aligned with the TCFD technical guidelines (FSB, 2017). We assessed the impacts of these physical hazards across time horizons to look beyond traditional business planning cycles; 2025, 2030 and 2050.

Physical climate scenarios RCP 2.6	Company-wide		In 2020, we partnered with S&P Global Trucost to perform a Climate Risk Assessment for Physical Risks. The analysis looked at on how physical hazards such as water stress, flooding, heatwave, cold wave, hurricane, wildfire and coastal flood risk might change along three climate change scenarios High Warming Scenario (RCP 8.5), Moderate Warming Scenario (RCP 4.5), and High Climate Mitigation Scenario (RCP 2.6). These scenarios are based on the IPCC's Representative Concentration Pathways (RCP) and are aligned with the TCFD technical guidelines (FSB, 2017). We assessed the impacts of these physical hazards across time horizons to look beyond traditional business planning cycles; 2025, 2030 and 2050.

C3.2b

(C3.2b) Provide details of the focal questions your organization seeks to address by using climate-related scenario analysis, and summarize the results with respect to these questions.

Row 1

Focal questions

How could the physical risks of climate change plausibly affect our company, what are the most material risks, and what are the short/medium/long term actions that need to be taken in regards to our business strategy and financial planning?

Results of the climate-related scenario analysis with respect to the focal questions

AbbVie's focus to discover and deliver innovative medicines and products to solve serious health issues remains constant. The climate-related risks that have been identified would not alter that mission for the benefit of both current and future patients. Climate-related risks, however, inform how we evaluate our operations and supply chains for potential disruptions in connection with climate change, implement contingency plans, and advance our preparedness. AbbVie has invested in business continuity efforts aimed at mitigating the potential for risk of loss and promoting business continuity in the event a climate-related risk materializes.

For example, AbbVie dedicates resources to assurance of supply activities, such as selecting redundant suppliers for raw materials, manufacturing products at multiple locations globally, and redundant shipping supply chains to deliver our products. The financial impact of these activities are evaluated within our annual and long-range financial planning cycles. The climate-related opportunities that have been identified require additional investment. AbbVie has established a centralized capital fund for global energy efficiency and decarbonization efforts.

C3.3

(C3.3) Describe where and how climate-related risks and opportunities have influenced your strategy.

	Have climate-related risks and opportunities influenced your strategy in this area?	Description of influence
Products and services	No	AbbVie has not experienced significant impact to our products from any of the identified risks or opportunities associated with climate change. We have not yet identified a climate risk that has resulted in a change to a product.
Supply chain and/or value chain	Yes	AbbVie has identified the increased severity of weather-related climate change events as a significant risk to our supply chains. Disruption to our supply chains can have a significant impact to the assurance of supply for our products and disruption to our patients access to the medicines they need. A significant supply chain interruption could result in a high financial impact. AbbVie has invested heavily in assurance of supply activities to help patients access the medicines they need. This includes redundant suppliers for raw materials, manufacturing products at multiple locations globally, and redundant shipping supply chains to deliver our products. In June of 2021, AbbVie committed to setting a Science Based Target. We have elected to pursue a supplier engagement target, and we AbbVie started have been developing a Supplier Engagement Strategy that will support a proposed supplier engagement target. Our proposed supplier engagement target will be to engage with our top suppliers that represent 79.1% of our Scope 3 emissions. This strategy is based on four pillars of direct supplier engagement, an annual supplier survey, a supplier awards program, and a supplier risk assessment. We are in process of rolling out these four elements of the strategy.
Investment in R&D	No	AbbVie has not pursued research and development within an area of unmet medical need that has come directly from a climate change related opportunity. Further, our risk mitigation activities related to climate change have not impacted our ability to invest in R&D in our therapeutic areas of focus.
Operations	Yes	AbbVie has identified the increased severity of climate-related weather events as having the potential to impact operations and supply chain. Disruption to our Operations

		sites could impact assurance of supply for our products, if resiliency plans are not implemented or effective. AbbVie invests in, and creates, business continuity plans to mitigate identified climate-related weather events. For example, AbbVie maintains a facility in Puerto Rico where product components are manufactured. Due to its location in the Caribbean, this site is at an increased risk of hurricane. To promote business continuity of operations, AbbVie has invested heavily in redundant manufacturing capabilities in Massachusetts and Singapore which would allow for a continuity of supply in the event the Puerto Rico location is unable to function. In 2018, AbbVie started the replacement of our co-generation system at our manufacturing site in Puerto Rico. This project represents a significant investment into the electrical resiliency of the site. The project was completed and put into service in 2019. AbbVie has invested in energy efficient technology to reduce our energy usage globally. AbbVie has established a capital fund to invest in energy efficiency and decarbonization projects at our global manufacturing sites.

C3.4

(C3.4) Describe where and how climate-related risks and opportunities have influenced your financial planning.

	Financial planning elements that have been influenced	Description of influence
Row 1	Direct costs Indirect costs Capital expenditures	AbbVie has identified the increased severity of climate-related weather events as having the potential to impact operations and supply chain. Disruption to our Operations sites could impact assurance of supply for our products, if resiliency plans are not implemented or effective. AbbVie has and will continue to invest in and create business continuity plans to mitigate identified climate-related weather events. AbbVie has invested heavily in assurance of supply activities including redundant suppliers for raw materials, manufacturing products at multiple locations globally, and redundant shipping supply chains to deliver our products. The financial impact of these activities are evaluated within our annual and long-range financial planning cycles. We realize that weather events may not only impact AbbVie but also the partners we rely on within AbbVie's supply chain. To mitigate climate-related disruptions to AbbVie's supply chain, AbbVie works with its

		supply chain partners to ensure they have continuity plans and makes investments itself in assurance of supply activities. This investment includes, but is not limited to, obtaining redundant suppliers for raw materials, manufacturing products at multiple locations globally, and using redundant shipping supply chains to deliver our products. The climate-related opportunities that have been identified require additional investment. AbbVie has established a centralized capital fund for global energy efficiency and decarbonization efforts.

C3.5

(C3.5) In your organization's financial accounting, do you identify spending/revenue that is aligned with your organization's climate transition?

	Identification of spending/revenue that is aligned with your organization's climate transition
Row 1	No, and we do not plan to in the next two years

C4. Targets and performance

C4.1

(C4.1) Did you have an emissions target that was active in the reporting year?

Absolute target

C4.1a

(C4.1a) Provide details of your absolute emissions target(s) and progress made against those targets.

Target reference number

Abs 1

Is this a science-based target?

Yes, and this target has been approved by the Science Based Targets initiative

Target ambition

1.5°C aligned

Year target was set

2022

Target coverage

Company-wide

Scope(s)

Scope 1
Scope 2

Scope 2 accounting method

Market-based

Scope 3 category(ies)

Base year

2021

Base year Scope 1 emissions covered by target (metric tons CO2e)

367,954

Base year Scope 2 emissions covered by target (metric tons CO2e)

256,708

Base year Scope 3, Category 1: Purchased goods and services emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 2: Capital goods emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 4: Upstream transportation and distribution emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 5: Waste generated in operations emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 6: Business travel emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 7: Employee commuting emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 8: Upstream leased assets emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 9: Downstream transportation and distribution emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 10: Processing of sold products emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 11: Use of sold products emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 12: End-of-life treatment of sold products emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 13: Downstream leased assets emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 14: Franchises emissions covered by target (metric tons CO2e)

Base year Scope 3, Category 15: Investments emissions covered by target (metric tons CO2e)

Base year Scope 3, Other (upstream) emissions covered by target (metric tons CO2e)

Base year Scope 3, Other (downstream) emissions covered by target (metric tons CO2e)

Base year total Scope 3 emissions covered by target (metric tons CO2e)

Total base year emissions covered by target in all selected Scopes (metric tons CO2e)

624,662

Base year Scope 1 emissions covered by target as % of total base year emissions in Scope 1

59

Base year Scope 2 emissions covered by target as % of total base year emissions in Scope 2

41

Base year Scope 3, Category 1: Purchased goods and services emissions covered by target as % of total base year emissions in Scope 3, Category 1: Purchased goods and services (metric tons CO2e)

Base year Scope 3, Category 2: Capital goods emissions covered by target as % of total base year emissions in Scope 3, Category 2: Capital goods (metric tons CO2e)

Base year Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions covered by target as % of total base year emissions in Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) (metric tons CO2e)

Base year Scope 3, Category 4: Upstream transportation and distribution covered by target as % of total base year emissions in Scope 3, Category 4: Upstream transportation and distribution (metric tons CO2e)

Base year Scope 3, Category 5: Waste generated in operations emissions covered by target as % of total base year emissions in Scope 3, Category 5: Waste generated in operations (metric tons CO2e)

Base year Scope 3, Category 6: Business travel emissions covered by target as % of total base year emissions in Scope 3, Category 6: Business travel (metric tons CO2e)

Base year Scope 3, Category 7: Employee commuting covered by target as % of total base year emissions in Scope 3, Category 7: Employee commuting (metric tons CO2e)

Base year Scope 3, Category 8: Upstream leased assets emissions covered by target as % of total base year emissions in Scope 3, Category 8: Upstream leased assets (metric tons CO2e)

Base year Scope 3, Category 9: Downstream transportation and distribution emissions covered by target as % of total base year emissions in Scope 3, Category 9: Downstream transportation and distribution (metric tons CO2e)

Base year Scope 3, Category 10: Processing of sold products emissions covered by target as % of total base year emissions in Scope 3, Category 10: Processing of sold products (metric tons CO2e)

Base year Scope 3, Category 11: Use of sold products emissions covered by target as % of total base year emissions in Scope 3, Category 11: Use of sold products (metric tons CO2e)

Base year Scope 3, Category 12: End-of-life treatment of sold products emissions covered by target as % of total base year emissions in Scope 3, Category 12: End-of-life treatment of sold products (metric tons CO2e)

Base year Scope 3, Category 13: Downstream leased assets emissions covered by target as % of total base year emissions in Scope 3, Category 13: Downstream leased assets (metric tons CO2e)

Base year Scope 3, Category 14: Franchises emissions covered by target as % of total base year emissions in Scope 3, Category 14: Franchises (metric tons CO2e)

Base year Scope 3, Category 15: Investments emissions covered by target as % of total base year emissions in Scope 3, Category 15: Investments (metric tons CO2e)

Base year Scope 3, Other (upstream) emissions covered by target as % of total base year emissions in Scope 3, Other (upstream) (metric tons CO2e)

Base year Scope 3, Other (downstream) emissions covered by target as % of total base year emissions in Scope 3, Other (downstream) (metric tons CO2e)

Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)

Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes

100

Target year

2030

Targeted reduction from base year (%)

42

Total emissions in target year covered by target in all selected Scopes (metric tons CO2e) [auto-calculated]

362,303.96

Scope 1 emissions in reporting year covered by target (metric tons CO2e)

342,607

Scope 2 emissions in reporting year covered by target (metric tons CO2e)

184,549

Scope 3, Category 1: Purchased goods and services emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 2: Capital goods emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 4: Upstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 5: Waste generated in operations emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 6: Business travel emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 7: Employee commuting emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 8: Upstream leased assets emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 9: Downstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 10: Processing of sold products emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 11: Use of sold products emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 12: End-of-life treatment of sold products emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 13: Downstream leased assets emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 14: Franchises emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Category 15: Investments emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Other (upstream) emissions in reporting year covered by target (metric tons CO2e)

Scope 3, Other (downstream) emissions in reporting year covered by target (metric tons CO2e)

Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)

Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)

527,156

Does this target cover any land-related emissions?

Yes, it covers land-related CO2 emissions/removals associated with bioenergy and non-land related emissions (e.g. non-FLAG SBT with bioenergy)

% of target achieved relative to base year [auto-calculated]

37.1652418199

Target status in reporting year

New

Please explain target coverage and identify any exclusions

The target covers 100% of AbbVie's Scope 1 and Scope 2 (Market Based) emissions. There are no exclusions.

Plan for achieving target, and progress made to the end of the reporting year

AbbVie established our near-term Science Based target in 2022, and the target has since been validated by SBTi in May of 2023. As part of the submission to SBTi, AbbVie included a written plan for our initiatives to achieve this target. The primary elements of the plan are as follows:
Implementation of energy efficiency and decarbonization projects across our Global manufacturing, R&D, and Commercial sites
Increasing active sourcing or renewable electricity to 100% by 2030
Electrification of our sales fleet vehicles resulting in at least a 42% reduction of Scope 1 emissions from our fleet by 2030
Consolidation of commercial real estate
Consolidation of our manufacturing and product portfolio

AbbVie made significant progress progress against our target in the first year achieving 37% of our target relative to our base year. The reductions in Scope 1 emissions were partially attributed to discontinuation of a legacy product at our North Chicago facility along with energy efficiency initiatives that were implemented across a number of our global facilities. The reductions in Scope 2 emissions were also partially attributed to discontinuation of the legacy product at our North Chicago facility, increased purchasing of renewable electricity, and implementation of energy efficiency initiatives across a number of our global facilities.

Note that previously AbbVie had set Absolute GHG reduction targets in 2016 for 2025 and 2035 respectively. AbbVie already exceeded the 25% GHG reduction target for 2025 at the end of 2021. The decision was made to sunset the 2025 target since it was achieved early, and the 2035 target was replaced with our near-term Science Based target described above.

List the emissions reduction initiatives which contributed most to achieving this target

C4.2

(C4.2) Did you have any other climate-related targets that were active in the reporting year?

Target(s) to increase low-carbon energy consumption or production
Other climate-related target(s)

C4.2a

(C4.2a) Provide details of your target(s) to increase low-carbon energy consumption or production.

Target reference number
Low 1

Year target was set
2022

Target coverage
Company-wide

Target type: energy carrier
Electricity

Target type: activity
Consumption

Target type: energy source
Renewable energy source(s) only

Base year
2021

Consumption or production of selected energy carrier in base year (MWh)
702,119

% share of low-carbon or renewable energy in base year
29

Target year
2030

% share of low-carbon or renewable energy in target year
100

% share of low-carbon or renewable energy in reporting year
42.7

% of target achieved relative to base year [auto-calculated]
19.2957746479

Target status in reporting year
New

Is this target part of an emissions target?
Yes - this target to increase active sourcing of renewable electricity to 100% by 2030 supports our Abs1 target detailed in C4.1, and this target is part of our validated near term Science Based Target.

Is this target part of an overarching initiative?
Science Based Targets initiative

Please explain target coverage and identify any exclusions

The target covers 100% of AbbVie's purchased electricity. There are no exclusions.

Plan for achieving target, and progress made to the end of the reporting year

AbbVie established our near-term Science Based target in 2022, and the target has since been validated by SBTi in May of 2023. As part of the submission to SBTi, AbbVie included a written plan for our initiatives to achieve this target. AbbVie is currently evaluating Power Purchase Agreements for renewable electricity for our operations in North America and Europe. This covers a significant portion of our emissions. For our other global locations we plan to source renewable electricity through agreements with our local utility providers or the direct purchase of energy attribute certificates.

List the actions which contributed most to achieving this target

C4.2b

(C4.2b) Provide details of any other climate-related targets, including methane reduction targets.

Target reference number

Oth 1

Year target was set

2016

Target coverage

Company-wide

Target type: absolute or intensity

Absolute

Target type: category & Metric (target numerator if reporting an intensity target)

Waste management
metric tons of waste generated

Target denominator (intensity targets only)

Base year

2015

Figure or percentage in base year

41,597

Target year

2025

Figure or percentage in target year

33,278

Figure or percentage in reporting year

33,212

% of target achieved relative to base year [auto-calculated]

100.7933645871

Target status in reporting year

Achieved

Is this target part of an emissions target?

Yes. In 2016 AbbVie decided to take a leadership approach to waste reduction by setting new targets to decrease the amount of waste that we generate. The target is to decrease the percentage by 20% by 2025 with a 2015 baseline. All quantities reported in this section are in Metric Tons of waste. Decreases in our on-site waste processing and handling have an impact on reducing our Scope 1 and Scope 2 emissions.

Is this target part of an overarching initiative?

No, it's not part of an overarching initiative

Please explain target coverage and identify any exclusions

This target covers 100% of AbbVie's Manufacturing and R&D sites around the globe. The target excludes construction and demolition waste.

Plan for achieving target, and progress made to the end of the reporting year

List the actions which contributed most to achieving this target

Waste reduction initiatives to reduce hazardous and non-hazardous waste.
Solvent recycling initiatives to reduce hazardous waste.
Initiatives to divert waste streams to beneficial re-use.

Target reference number

Oth 2

Year target was set

2022

Target coverage

Company-wide

Target type: absolute or intensity

Absolute

Target type: category & Metric (target numerator if reporting an intensity target)

Engagement with suppliers

Percentage of suppliers (by emissions) with a science-based target

Target denominator (intensity targets only)

Base year

2021

Figure or percentage in base year

13

Target year

2027

Figure or percentage in target year

78.1

Figure or percentage in reporting year

23

% of target achieved relative to base year [auto-calculated]

15.3609831029

Target status in reporting year

New

Is this target part of an emissions target?

No

Is this target part of an overarching initiative?

Science Based Targets initiative – approved supplier engagement target

Please explain target coverage and identify any exclusions

The text of our approved supplier engagement target is as follows: AbbVie commits that 79.1% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027.

Plan for achieving target, and progress made to the end of the reporting year

AbbVie established our near-term Science Based target in 2022, and the target has since been validated by SBTi in May of 2023. As part of the submission to SBTi, AbbVie included a written plan for our initiatives to achieve this target. AbbVie has established a supplier engagement program to support the achievement of this target. In our 2021 baseline year, 13.4% of AbbVie's suppliers by emissions had an approved SBT. In 2022, this percentage increased to 23.0%.

List the actions which contributed most to achieving this target

C4.3

(C4.3) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.

Yes

C4.3a

(C4.3a) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings.

	Number of initiatives	Total estimated annual CO2e savings in metric tonnes CO2e (only for rows marked *)
Under investigation	10	894
To be implemented*	11	2,442
Implementation commenced*	56	15,306
Implemented*	30	78,120
Not to be implemented	12	384

C4.3b

(C4.3b) Provide details on the initiatives implemented in the reporting year in the table below.

Initiative category & Initiative type

Energy efficiency in buildings

Heating, Ventilation and Air Conditioning (HVAC)

Estimated annual CO2e savings (metric tonnes CO2e)

542

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 1

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

318

Investment required (unit currency – as specified in C0.4)

1,218

Payback period

4-10 years

Estimated lifetime of the initiative

16-20 years

Comment

AbbVie implemented a series of HVAC projects at our global Manufacturing sites that replace the existing HVAC units or improve the overall efficiency of the units.

Initiative category & Initiative type

Energy efficiency in buildings
Heating, Ventilation and Air Conditioning (HVAC)

Estimated annual CO2e savings (metric tonnes CO2e)

1,454

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 2 (location-based)

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

704

Investment required (unit currency – as specified in C0.4)

2,005

Payback period

1-3 years

Estimated lifetime of the initiative

16-20 years

Comment

AbbVie implemented a series of HVAC projects at our global Manufacturing sites that replace the existing HVAC units or improve the overall efficiency of the units.

Initiative category & Initiative type

Energy efficiency in buildings
Building Energy Management Systems (BEMS)

Estimated annual CO2e savings (metric tonnes CO2e)

131

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 1

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

49

Investment required (unit currency – as specified in C0.4)

90

Payback period

1-3 years

Estimated lifetime of the initiative

6-10 years

Comment

AbbVie implemented projects at our North Chicago and Abbott Park sites to supplement the existing Building EMS to improve the overall efficiency of the utility systems such as the boilers, chillers, and HVAC.

Initiative category & Initiative type

Energy efficiency in buildings
Lighting

Estimated annual CO2e savings (metric tonnes CO2e)

48

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 2 (location-based)

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

8

Investment required (unit currency – as specified in C0.4)

144

Payback period

16-20 years

Estimated lifetime of the initiative

16-20 years

Comment

AbbVie implemented a lighting project at a global manufacturing site that replaced the existing lights to improve the overall efficiency of lighting.

Initiative category & Initiative type

Energy efficiency in production processes
Compressed air

Estimated annual CO2e savings (metric tonnes CO2e)

1,000

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 2 (location-based)

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

140

Investment required (unit currency – as specified in C0.4)

70

Payback period

<1 year

Estimated lifetime of the initiative

16-20 years

Comment

AbbVie completed an energy efficiency project on the compressed air system at the North Chicago facility improving the overall efficiency of the compressed air system.

Initiative category & Initiative type

Energy efficiency in production processes
Cooling technology

Estimated annual CO2e savings (metric tonnes CO2e)

101

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 2 (location-based)

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

40

Investment required (unit currency – as specified in C0.4)

100

Payback period

1-3 years

Estimated lifetime of the initiative

16-20 years

Comment

AbbVie implemented a number of chillers and chilled water distribution systems improvement projects at our global manufacturing sites that improves the overall efficiency of the chillers and the chilled water distribution systems.

Initiative category & Initiative type

Energy efficiency in production processes
Motors and drives

Estimated annual CO2e savings (metric tonnes CO2e)

131

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 2 (location-based)

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

48

Investment required (unit currency – as specified in C0.4)

90

Payback period

1-3 years

Estimated lifetime of the initiative

16-20 years

Comment

AbbVie installed VSDs on fire protection and hot water systems improving the overall efficiency of both the fire protection and hot water systems.

Initiative category & Initiative type

Energy efficiency in production processes
Waste heat recovery

Estimated annual CO2e savings (metric tonnes CO2e)

336

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 1

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

75

Investment required (unit currency – as specified in C0.4)

296

Payback period

4-10 years

Estimated lifetime of the initiative

16-20 years

Comment

AbbVie implemented a number of heat recovery and heat pump projects at our global manufacturing sites that recover waste heat and improves the overall efficiency of the heating systems.

Initiative category & Initiative type

Low-carbon energy generation
Solar PV

Estimated annual CO2e savings (metric tonnes CO2e)

65

Scope(s) or Scope 3 category(ies) where emissions savings occur

Scope 2 (location-based)

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

21

Investment required (unit currency – as specified in C0.4)

80

Payback period

4-10 years

Estimated lifetime of the initiative

16-20 years

Comment

AbbVie installed a solar PV expansion at a global site.

Initiative category & Initiative type

Company policy or behavioral change
Site consolidation/closure

Estimated annual CO2e savings (metric tonnes CO2e)
21,483

Scope(s) or Scope 3 category(ies) where emissions savings occur
Scope 1

Voluntary/Mandatory
Voluntary

Annual monetary savings (unit currency – as specified in C0.4)
5,554,592

Investment required (unit currency – as specified in C0.4)
0

Payback period
<1 year

Estimated lifetime of the initiative
Ongoing

Comment
There were a number of increases and decreases in manufacturing volumes at the various manufacturing sites globally. This included the discontinuing of a legacy energy-intensive product in our North Chicago facility which decreased fuel burned on site resulting in a significant reduction in Scope 1 GHG Emissions.

Initiative category & Initiative type
Company policy or behavioral change
Site consolidation/closure

Estimated annual CO2e savings (metric tonnes CO2e)
52,829

Scope(s) or Scope 3 category(ies) where emissions savings occur
Scope 2 (market-based)

Voluntary/Mandatory
Voluntary

Annual monetary savings (unit currency – as specified in C0.4)
627,151

Investment required (unit currency – as specified in C0.4)
0

Payback period

<1 year

Estimated lifetime of the initiative

Ongoing

Comment

There were a number of increases and decreases in manufacturing volumes at the various manufacturing sites globally. This included the discontinuing of a legacy energy-intensive product in our North Chicago facility which decreased electricty consumed resulting in a significant reduction in Scope 2 GHG Emissions.

C4.3c

(C4.3c) What methods do you use to drive investment in emissions reduction activities?

Method	Comment
Dedicated budget for energy efficiency	AbbVie has a dedicated corporate energy capital fund. The global manufacturing sites apply for this funding to complete energy reduction, cost reduction and emission reduction projects. In addition, each site can use funds from their respective site capital budgets to execute energy projects. In 2022 a total of 28 energy reduction and energy resilience projects were approved and funded by the corporate energy capital fund. Projects included a heat pump, replacement of air-handing units, heat recovery, chiller efficiency upgrades, insulation upgrades, and HVAC efficiency upgrades. This fund was $5,800,000 in 2022.
Dedicated budget for other emissions reduction activities	AbbVie has a dedicated corporate decarbonization capital fund. Projects here are selected based on the CO2 reduction primarily (i.e. the "metric Tonne/$000 investment" metric is used to stack-rank projects, with a preference for fuel reduction projects). All areas of the company apply for this funding to complete emission reduction projects. In addition, each area can use funds from their respective site capital budgets to execute decarbonization projects. In 2022 a total of 21 decarbonization reduction projects were approved and funded by the decarbonization capital fund. Projects included installation of variable-speed drives, solar (hot water), lighting projects, replacement of HVAC chillers, and steam trap sensors. This fund was $5,000,000 in 2022. In addition, AbbVie has a dedicated corporate environmental capital fund. The global manufacturing sites apply for this funding to complete energy, water, and waste reduction projects. This fund was $1,100,000 in 2022.
Employee engagement	AbbVie has a global energy team that meets monthly. These meetings communicate on AbbVie science-based targets program, ISO 50001, Energy Star, the energy and decarbonization capital fund timings, share best practices, opportunities and lessons learned. The meeting is open to a diverse group of energy managers, sustainability leads, engineers, EHS personnel, and our Purchasing & Supplier Management group. This drives investments because others can share best practices and leverage internal experience and

	expertise to overcome obstacles and challenges as well as fostering a team-based approach to energy management. In addition, there is engagement of all employees to operate efficiently, reduce energy usage, and reduce our carbon footprint. AbbVie facilitates an annual innovation accelerator program for environmental sustainability. In 2022, colleagues from 22 different global sites submitted over 112 ideas. For the second year running, on Earth Day 2022, we launched an employee sustainability engagement campaign called EcoChallenge to encourage the adoption of sustainable behaviors at work and at home. Over 109,906 sustainable actions were completed by 3,674 colleagues in 295team from 58 different countries.
Lower return on investment (ROI) specification	AbbVie has an internal return on investment specification of 20% Internal Rate of Return (IRR) for projects to be classified as financially justified. This is calculated using a DCF-ROI model that AbbVie developed. Many of the energy projects that were funded were approved with a lower IRR in the 15% to 20% range. Many of the environmental projects that were funded had low or no IRR. Projects funded from the corporate decarbonization capital fund are selected based on the CO2 reduction primarily (i.e. the "metric Tonne/$000 investment" metric is used to stack-rank projects, with a preference for fuel reduction projects). In 2022 a total of 21 decarbonization reduction projects were approved and funded by the decarbonization capital fund.

C4.5

(C4.5) Do you classify any of your existing goods and/or services as low-carbon products?

No

C5. Emissions methodology

C5.1

(C5.1) Is this your first year of reporting emissions data to CDP?

No

C5.1a

(C5.1a) Has your organization undergone any structural changes in the reporting year, or are any previous structural changes being accounted for in this disclosure of emissions data?

Row 1

Has there been a structural change?

No

C5.1b

(C5.1b) Has your emissions accounting methodology, boundary, and/or reporting year definition changed in the reporting year?

	Change(s) in methodology, boundary, and/or reporting year definition?
Row 1	No

C5.2

(C5.2) Provide your base year and base year emissions.

Scope 1

Base year start
January 1, 2015

Base year end
December 31, 2015

Base year emissions (metric tons CO2e)
402,448

Comment
The Scope 1 base year emissions reported above were recalculated in 2021 to include both AbbVie + Allergan, PLC for 2015.

Scope 2 (location-based)

Base year start
January 1, 2015

Base year end
December 31, 2015

Base year emissions (metric tons CO2e)
419,061

Comment
The Scope 2 (location) base year emissions reported above were recalculated in 2021 to include both AbbVie + Allergan, PLC for 2015.

Scope 2 (market-based)

Base year start
January 1, 2015

Base year end
December 31, 2015

Base year emissions (metric tons CO2e)

418,473

Comment

The Scope 2 (Market) base year emissions reported above were recalculated in 2021 to include both AbbVie + Allergan, PLC for 2015.

For scope 3 information, please see www.cdp.net.

C5.3

(C5.3) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions.

IEA CO2 Emissions from Fuel Combustion
The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition)
US EPA Mandatory Greenhouse Gas Reporting Rule
US EPA Emissions & Generation Resource Integrated Database (eGRID)

C6. Emissions data

C6.1

(C6.1) What were your organization's gross global Scope 1 emissions in metric tons CO2e?

Reporting year

Gross global Scope 1 emissions (metric tons CO2e)

342,607

Comment

No comment.

C6.2

(C6.2) Describe your organization's approach to reporting Scope 2 emissions.

Row 1

Scope 2, location-based

We are reporting a Scope 2, location-based figure

Scope 2, market-based

We are reporting a Scope 2, market-based figure

Comment

No comment.

C6.3

(C6.3) What were your organization's gross global Scope 2 emissions in metric tons CO2e?

Reporting year

Scope 2, location-based

271,055

Scope 2, market-based (if applicable)

184,549

Comment

No comment.

C6.4

(C6.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1, Scope 2 or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure?

No

C6.5

(C6.5) Account for your organization's gross global Scope 3 emissions, disclosing and explaining any exclusions.

For scope 3 information, please see www.cdp.net.

C6.7

(C6.7) Are carbon dioxide emissions from biogenic carbon relevant to your organization?

No

C6.10

(C6.10) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations.

Intensity figure

9.08

Metric numerator (Gross global combined Scope 1 and 2 emissions, metric tons CO2e)

527,156

Metric denominator

unit total revenue

Metric denominator: Unit total

58,054

Scope 2 figure used

Market-based

% change from previous year

18.3

Direction of change

Decreased

Reason(s) for change

Change in renewable energy consumption
Other emissions reduction activities
Change in output

Please explain

The intensity figure reported above is Metric Tons CO2e / USD$ Millions Revenue. Abbvie increased the amount of renewable energy that was consumed from 29.5% in 2021 to 42.7% in 2022. In addition, AbbVie discontinued the manufacture of a legacy product at our North Chicago facility which resulted in significant decreases in fuel and electricity and the associated Scope 1&2 emissions. In addition, AbbVie implemented a number of energy efficiency and decarbonization projects at our global sites.

C7. Emissions breakdowns

C7.1

(C7.1) Does your organization break down its Scope 1 emissions by greenhouse gas type?

Yes

C7.1a

(C7.1a) Break down your total gross global Scope 1 emissions by greenhouse gas type and provide the source of each used greenhouse warming potential (GWP).

Greenhouse gas	Scope 1 emissions (metric tons of CO2e)	GWP Reference

CO2	336,027	IPCC Fourth Assessment Report (AR4 - 50 year)
CH4	478	IPCC Fourth Assessment Report (AR4 - 50 year)
N2O	1,017	IPCC Fourth Assessment Report (AR4 - 50 year)
Other, please specify All Refrigerants (HFC's, PFC's, etc)	5,085	IPCC Fourth Assessment Report (AR4 - 50 year)
SF6	0	IPCC Fourth Assessment Report (AR4 - 50 year)
NF3	0	IPCC Fourth Assessment Report (AR4 - 50 year)

C7.2

(C7.2) Break down your total gross global Scope 1 emissions by country/area/region.

Country/area/region	Scope 1 emissions (metric tons CO2e)
Algeria	43
Egypt	500
Morocco	18
Tunisia	26
South Africa	342
Argentina	144
Brazil	3,291
Canada	2,404
Chile	41
Colombia	185
Costa Rica	12
Dominican Republic	19
Guatemala	12
Honduras	0
Mexico	782
Nicaragua	0
Panama	10
Peru	0
Puerto Rico	70,890
El Salvador	0

Uruguay	20
United States of America	151,032
United Arab Emirates	224
Bahrain	11
China	354
Hong Kong SAR, China	16
Israel	636
Jordan	18
Japan	2,572
Kazakhstan	13
Republic of Korea	773
Kuwait	59
Lebanon	264
Malaysia	31
Oman	15
Qatar	10
Saudi Arabia	330
Singapore	14,346
Thailand	1,159
Turkey	2,094
Taiwan, China	560
Austria	499
Belgium	871
Bulgaria	186
Bosnia & Herzegovina	22
Belarus	13
Switzerland	255
Germany	25,386
Denmark	197
Spain	1,637
Estonia	56
Finland	18
France	3,284
United Kingdom of Great Britain and Northern Ireland	1,063
Greece	412

Croatia	148
Hungary	220
Ireland	22,822
Italy	26,467
Lithuania	118
Latvia	52
Netherlands	701
Norway	66
Poland	879
Portugal	394
Romania	214
Russian Federation	872
Serbia	42
Slovakia	459
Slovenia	104
Sweden	346
Ukraine	66
Australia	182
New Zealand	50
Indonesia	0
India	1,202
Philippines	31
Viet Nam	1
Czechia	16
Luxembourg	0

C7.3

(C7.3) Indicate which gross global Scope 1 emissions breakdowns you are able to provide.

By business division
By facility
By activity

C7.3a

(C7.3a) Break down your total gross global Scope 1 emissions by business division.

Business division	Scope 1 emissions (metric ton CO2e)

Operations	99,759
Commercial	220,954
Headquarters	11,021
R&D	10,873

C7.3b

(C7.3b) Break down your total gross global Scope 1 emissions by business facility.

Facility	Scope 1 emissions (metric tons CO2e)	Latitude	Longitude
Abbott Park, USA	1,719	42.302	-87.892
Barceloneta, Puerto Rico (ABL)	1,024	18.428	-66.575
Barceloneta, Puerto Rico (AbbVie Ltd, APL)	69,867	18.435	-66.565
Campoverde, Italy	23,776	41.551	12.704
Cork, Ireland	2,867	51.894	-8.485
Ludwigshaven, Germany	21,806	49.475	8.435
North Chicago, USA	45,757	42.332	-87.835
Sligo, Ireland	4,100	54.285	-8.453
Sligo Ballytivnan, Ireland	2,272	54.286	-8.464
Worcester, USA	8,767	42.275	-71.77
Wyandotte, USA	1	42.218	-83.15
Lake County, USA Various Buildings	10,674	42.302	-87.892
Other, Worldwide Commercial Offices	99,759	0	0
Tuas, Singapore	14,198	1.302	103.633
South San Francisco (Pharmacyclics), USA	0	37.382	-122.004
Cambridge, USA	391	42.374	-71.109
Branchburg, USA	808	40.56417	-74.71059
Campbell, USA	718	37.26555	-121.95701
Cincinnati, USA	1,231	39.15325	-84.407222
Clonshaugh, Ireland	4,068	53.40274	-6.22185
Dublin , USA	39	37.704679	-121.91372
Galway, Ireland	35	35.27615	-9.09412
Guarulhos, Brazil	1,076	-23.49485	-46.54857

Heredia, Costa Rica	0	9.99184	-84.15761
Houston, USA	217	29.82381	-95.46133
Irvine, USA	9,135	33.67208	-117.85428
Liege, Belgium	115	50.65731	5.49957
Livermore, USA	44	37.70757	-121.70615
Pleasanton, USA	164	37.69913	-121.88267
Pringy, France	1,277	45.95158	6.11327
Waco, USA	5,545	31.48697	-97.2016
Westport, Ireland	9,236	53.80614	-9.51296
Madison, USA	347	40.76316	-74.43582
Bridgewater, USA	55	40.58792	-74.62614
Santa Cruz, USA	7	36.9546	-122.05415
Sunrise, USA	1	26.12311	-80.33601
South San Francisco, USA	1,284	37.662	-122.39515
Lod, Israel	227	32.149961	34.883879

C7.3c

(C7.3c) Break down your total gross global Scope 1 emissions by business activity.

Activity	Scope 1 emissions (metric tons CO2e)
Stationary Combustion	227,346
Mobile Combustion	104,510
Fugitive Emissions	5,319
Office Activities	5,432

C7.5

(C7.5) Break down your total gross global Scope 2 emissions by country/area/region.

Country/area/region	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)
Algeria	54	54
Egypt	155	155
Morocco	32	32
Tunisia	77	77

South Africa	568	568
Argentina	177	177
Brazil	795	144
Canada	248	248
Chile	35	35
Colombia	61	61
Costa Rica	50	50
Dominican Republic	3	3
Guatemala	1	1
Honduras	0	0
Mexico	191	191
Nicaragua	0	0
Panama	0	0
Peru	0	0
Puerto Rico	171	171
El Salvador	0	0
Uruguay	1	1
United States of America	209,967	147,633
United Arab Emirates	320	320
Bahrain	0	0
China	2,095	2,095
Hong Kong SAR, China	115	115
Israel	1,230	1,230
Jordan	24	24
Japan	1,548	1,548
Kazakhstan	10	10
Republic of Korea	582	582
Kuwait	0	0
Lebanon	181	181
Malaysia	220	220
Oman	0	0
Qatar	0	0
Saudi Arabia	269	269
Singapore	16,249	20,410
Thailand	186	186

Turkey	583	583
Taiwan, China	492	492
Austria	55	55
Belgium	248	128
Bulgaria	80	80
Bosnia & Herzegovina	22	22
Belarus	4	4
Switzerland	16	16
Germany	5,922	688
Denmark	39	39
Spain	300	300
Estonia	30	30
Finland	15	15
France	682	682
United Kingdom of Great Britain and Northern Ireland	740	740
Greece	171	171
Croatia	23	23
Hungary	42	42
Ireland	22,058	176
Italy	889	443
Lithuania	6	6
Latvia	12	12
Netherlands	373	373
Norway	1	1
Poland	500	500
Portugal	79	79
Romania	155	155
Russian Federation	305	305
Serbia	36	36
Slovakia	75	75
Slovenia	25	25
Sweden	6	6
Ukraine	81	81
Australia	595	595
New Zealand	9	9

Luxembourg	1	1
Venezuela (Bolivarian Republic of)	0	0
Indonesia	0	0
India	574	574
Oman	0	0
Philippines	189	189
Viet Nam	7	7
Czechia	0	0

C7.6

(C7.6) Indicate which gross global Scope 2 emissions breakdowns you are able to provide.

By business division
By facility
By activity

C7.6a

(C7.6a) Break down your total gross global Scope 2 emissions by business division.

Business division	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)
Operations	227,121	150,297
Commercial	20,442	20,442
Headquarters	12,368	7,678
Research and Development	11,124	6,132

C7.6b

(C7.6b) Break down your total gross global Scope 2 emissions by business facility.

Facility	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)
Abbott Park, USA	84,238	66,263
Barceloneta, Puerto Rico (ABL)	0	0
Barceloneta, Puerto Rico (AbbVie Ltd, APL)	9,996	9,996
Campoverde, Italy	447	0
Cork, Ireland	2,458	0
Ludwigshaven, Germany	5,234	0

North Chicago, USA	56,100	28,050
Sligo Manorhamilton, Ireland	2,915	0
Sligo Ballytivnan, Ireland	2,538	0
Worcester, USA	6,972	6,972
Wyandotte, USA	2,322	2,034
Lake County, USA (Various Buildings)	6,781	3,391
Other (Worldwide Commercial Offices)	20,442	20,442
Tuas, Singapore	15,833	19,994
South San Francisco (Pharmacyclics), USA	5	5
Cambridge, USA	215	215
Livermore, USA	25	0
Branchburg, USA	7,446	7,446
Campbell, USA	464	0
Cincinnati, USA	2,602	2,602
Clonshaugh, USA	2,354	0
Dublin, USA	111	17
Galway, Ireland	47	0
Guarulhos, Brazil	651	0
Heredia, Costa Rica	50	50
Houston, USA	486	0
Liege, Belgium	120	0
Pleasanton, USA	207	207
Pringy, France	536	536
Waco, USA	10,539	5,269
Westport, Ireland	11,570	0
Madison, USA	5,587	4,288
Bridgewater, USA	369	369
Irvine, USA	7,906	3,953
Santa Cruz, USA	11	11
Sunrise	539	539
AbbVie Bay Area South San Francisco	2,078	1,039
AbbVie Israel	861	861

C7.6c

(C7.6c) Break down your total gross global Scope 2 emissions by business activity.

Activity	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)
Operations Activities (Manufacturing, Warehouse, etc.)	227,121	150,297
Office Activities (Commercial Office Spaces, Leased Offices)	32,810	28,120
Research and Development	11,124	6,132

C7.7

(C7.7) Is your organization able to break down your emissions data for any of the subsidiaries included in your CDP response?

Not relevant as we do not have any subsidiaries

C7.9

(C7.9) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?

Decreased

C7.9a

(C7.9a) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined), and for each of them specify how your emissions compare to the previous year.

	Change in emissions (metric tons CO2e)	Direction of change in emissions	Emissions value (percentage)	Please explain calculation
Change in renewable energy consumption	12,268	Decreased	2.327	In 2021 we generated 624,662 of CO2e and in 2022 we generated 527,156 MT. Overall this is a decrease of 97,506 MT. Our Renewable Energy Strategy accounted for a 12,268,111 MT decrease of CO2e (12,268/624,662) X 100 = 2.327% decrease due to purchasing renewable electricity.
Other emissions reduction activities	3,815	Decreased	0.724	Our energy efficiency and decarbonization emissions reduction strategy accounted for 3,815 MT of CO2e. (3,815/624,662) X 100 = 0.724%

				decrease due to energy efficiency projects.
Divestment	215	Decreased	0.041	In 2022, there was a divestment of one AbbVie location resulting in a reduction of 215 MT of CO2e. (215/624,662) X 100 = 0.041% decrease due to Divestment.
Acquisitions	0	No change	0	There was no acquisitions in 2022.
Mergers	0	No change	0	There was no mergers in 2022.
Change in output	74,312	Decreased	14.097	There were a number of increases and decreases in manufacturing volumes (output) at the various manufacturing sites globally. This included the discontinuing of a legacy energy-intensive product in our North Chicago facility which resulted in a significant reduction in gross GHG Emissions at that site. The net change in output was a decrease of 74,312 MT. (74,312/624,662) X 100 = 14.097% decrease due to change in output.
Change in methodology	0	No change	0	There was no change in methodology in 2022.
Change in boundary	0	No change	0	There was no change in boundary in 2022.
Change in physical operating conditions	0	No change	0	There was no change in physical operating conditions in 2022.
Unidentified	0	No change	0	There was no change in Unidentified in 2022.
Other	6,896	Decreased	1.308	There were a number of consolidations within our manufacturing locations that resulted in energy efficiency improvements resulting in a decrease of 6,896 MT. (6,896/624,662) X 100 = 1.308% decrease due to Other.

C7.9b

(C7.9b) Are your emissions performance calculations in C7.9 and C7.9a based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure?

Market-based

C8. Energy

C8.1

(C8.1) What percentage of your total operational spend in the reporting year was on energy?

More than 0% but less than or equal to 5%

C8.2

(C8.2) Select which energy-related activities your organization has undertaken.

	Indicate whether your organization undertook this energy-related activity in the reporting year
Consumption of fuel (excluding feedstocks)	Yes
Consumption of purchased or acquired electricity	Yes
Consumption of purchased or acquired heat	No
Consumption of purchased or acquired steam	Yes
Consumption of purchased or acquired cooling	Yes
Generation of electricity, heat, steam, or cooling	Yes

C8.2a

(C8.2a) Report your organization's energy consumption totals (excluding feedstocks) in MWh.

	Heating value	MWh from renewable sources	MWh from non-renewable sources	Total (renewable and non-renewable) MWh
Consumption of fuel (excluding feedstock)	HHV (higher heating value)	0	1,647,673	1,647,673
Consumption of purchased or acquired electricity		245,115	441,337	686,452
Consumption of purchased or acquired steam		0	135,213	135,213

Consumption of purchased or acquired cooling		0	93,946	93,946
Consumption of self-generated non-fuel renewable energy		1,949		1,949
Total energy consumption		247,064	2,318,169	2,565,233

C8.2b

(C8.2b) Select the applications of your organization's consumption of fuel.

	Indicate whether your organization undertakes this fuel application
Consumption of fuel for the generation of electricity	Yes
Consumption of fuel for the generation of heat	Yes
Consumption of fuel for the generation of steam	Yes
Consumption of fuel for the generation of cooling	No
Consumption of fuel for co-generation or tri-generation	Yes

C8.2c

(C8.2c) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type.

Sustainable biomass

Heating value

Unable to confirm heating value

Total fuel MWh consumed by the organization

0

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self- cogeneration or self-trigeneration

0

Comment

Not applicable. No sustainable biomass fuel is consumed.

Other biomass

Heating value

Unable to confirm heating value

Total fuel MWh consumed by the organization

0

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self- cogeneration or self-trigeneration

0

Comment

Not applicable. No other biomass fuel is consumed.

Other renewable fuels (e.g. renewable hydrogen)

Heating value

Unable to confirm heating value

Total fuel MWh consumed by the organization

0

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self- cogeneration or self-trigeneration

0

Comment

Not applicable. No other renewable fuel is consumed.

Coal

Heating value

Unable to confirm heating value

Total fuel MWh consumed by the organization

0

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self- cogeneration or self-trigeneration

0

Comment

Not applicable. No coal fuel is consumed.

Oil

Heating value

HHV

Total fuel MWh consumed by the organization

449,954

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

134,986

MWh fuel consumed for self-generation of steam

314,968

MWh fuel consumed for self- cogeneration or self-trigeneration

0

Comment

This includes Jet kerosene, Distillate fuel oil No. 2, and other Motor Vehicle Fuels.

Gas

Heating value

HHV

Total fuel MWh consumed by the organization

1,149,945

MWh fuel consumed for self-generation of electricity

502,301

MWh fuel consumed for self-generation of heat

194,293

MWh fuel consumed for self-generation of steam

453,351

MWh fuel consumed for self- cogeneration or self-trigeneration

0

Comment

This includes both Natural Gas and Liquified Natural Gas (LNG) fuels. Many of the AbbVie global sites do not have adequate sub-metering to accurately differentiate how much natural gas or LNG fuel is used to generate heat versus steam. An engineering estimate was used to divide the natural gas and LNG fuel consumption for generating heat versus steam.

Other non-renewable fuels (e.g. non-renewable hydrogen)

Heating value

HHV

Total fuel MWh consumed by the organization

47,774

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

14,332

MWh fuel consumed for self-generation of steam

33,442

MWh fuel consumed for self- cogeneration or self-trigeneration

0

Comment

This includes LPG and Propane fuel.

Total fuel

Heating value

HHV

Total fuel MWh consumed by the organization

1,647,673

MWh fuel consumed for self-generation of electricity

502,301

MWh fuel consumed for self-generation of heat

343,611

MWh fuel consumed for self-generation of steam

801,761

MWh fuel consumed for self- cogeneration or self-trigeneration

0

Comment

Many of the AbbVie global sites do not have adequate sub-metering to accurately differentiate how much fuel is used to generate heat versus steam. An engineering estimate was used to divide the fuel consumption for generating heat versus steam.

C8.2d

(C8.2d) Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year.

	Total Gross generation (MWh)	Generation that is consumed by the organization (MWh)	Gross generation from renewable sources (MWh)	Generation from renewable sources that is consumed by the organization (MWh)
Electricity	176,865	169,704	1,792	1,792
Heat	194,270	194,270	0	0
Steam	327,381	327,181	0	0
Cooling	343,226	281,009	122,558	122,558

C8.2e

(C8.2e) Provide details on the electricity, heat, steam, and/or cooling amounts that were accounted for at a zero or near-zero emission factor in the market-based Scope 2 figure reported in C6.3.

Country/area of low-carbon energy consumption

United States of America

Sourcing method

Unbundled procurement of energy attribute certificates (EACs)

Energy carrier

Electricity

Low-carbon technology type

Wind

Low-carbon energy consumed via selected sourcing method in the reporting year (MWh)

145,339

Tracking instrument used

US-REC

Country/area of origin (generation) of the low-carbon energy or energy attribute

United States of America

Are you able to report the commissioning or re-powering year of the energy generation facility?

Yes

Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2022

Comment

U.S. REC's are sourced and retired through the electric suppliers.

Country/area of low-carbon energy consumption

Ireland

Sourcing method

Default delivered electricity from the grid (e.g. standard product offering by an energy supplier), supported by energy attribute certificates

Energy carrier

Electricity

Low-carbon technology type

Wind

Low-carbon energy consumed via selected sourcing method in the reporting year (MWh)

74,242

Tracking instrument used

GO

Country/area of origin (generation) of the low-carbon energy or energy attribute

Ireland

Are you able to report the commissioning or re-powering year of the energy generation facility?

Yes

Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2022

Comment

Irish GO's are sourced and retired through our local electric supplier. AbbVie has a contract in place with our electric supplier to source the GO's for 100% of our purchased electricity and then retires them on our behalf. Our supplier does this as a program for multiple customers and does not currently provide us with specific data on the generation facility of origin for the GO's.

Country/area of low-carbon energy consumption

Germany

Sourcing method

Unbundled procurement of energy attribute certificates (EACs)

Energy carrier

Electricity

Low-carbon technology type

Small hydropower (<25 MW)

Low-carbon energy consumed via selected sourcing method in the reporting year (MWh)

15,192

Tracking instrument used

GO

Country/area of origin (generation) of the low-carbon energy or energy attribute

Norway

Are you able to report the commissioning or re-powering year of the energy generation facility?

Yes

Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2022

Comment

German GO's are sourced and retired through our local electric supplier. AbbVie has a contract in place with our electric supplier to source the GO's for 100% of our purchased electricity and then retires them on our behalf. Our supplier does this as a program for multiple customers and does not currently provide us with specific data on the generation facility of origin for the GO's.

Country/area of low-carbon energy consumption

Italy

Sourcing method

Unbundled procurement of energy attribute certificates (EACs)

Energy carrier

Electricity

Low-carbon technology type

Solar

Low-carbon energy consumed via selected sourcing method in the reporting year (MWh)

1,567

Tracking instrument used

GO

Country/area of origin (generation) of the low-carbon energy or energy attribute

Italy

Are you able to report the commissioning or re-powering year of the energy generation facility?

Yes

Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2022

Comment

Italian GO's are sourced and retired through our local electric supplier. AbbVie has a contract in place with our electric supplier to source the GO's for 100% of our purchased electricity and then retires them on our behalf. Our supplier does this as a program for multiple customers and does not currently provide us with specific data on the generation facility of origin for the GO's.

Country/area of low-carbon energy consumption

Brazil

Sourcing method

Unbundled procurement of energy attribute certificates (EACs)

Energy carrier

Electricity

Low-carbon technology type

Hydropower (capacity unknown)

Low-carbon energy consumed via selected sourcing method in the reporting year (MWh)

6,254

Tracking instrument used

I-REC

Country/area of origin (generation) of the low-carbon energy or energy attribute

Brazil

Are you able to report the commissioning or re-powering year of the energy generation facility?

No

Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

Comment

Brazil iREC's are sourced and retired through our local electric supplier. AbbVie has a contract in place with our electric supplier to source the iREC's and then retires them on our behalf. Our supplier does this as a program for multiple customers and does not currently provide us with specific data on the generation facility of origin for the iREC's.

Country/area of low-carbon energy consumption

Belgium

Sourcing method

Unbundled procurement of energy attribute certificates (EACs)

Energy carrier

Electricity

Low-carbon technology type

Wind

Low-carbon energy consumed via selected sourcing method in the reporting year (MWh)

729

Tracking instrument used

GO

Country/area of origin (generation) of the low-carbon energy or energy attribute

Belgium

Are you able to report the commissioning or re-powering year of the energy generation facility?

No

Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

Comment

Belgian GO's are sourced and retired through our local electric supplier. AbbVie has a contract in place with our electric supplier to source the GO's for 100% of our purchased electricity and then retires them on our behalf. Our supplier does this as a program for multiple customers and does not currently provide us with specific data on the generation facility of origin for the GO's

C8.2g

(C8.2g) Provide a breakdown by country/area of your non-fuel energy consumption in the reporting year.

Country/area

Brazil

Consumption of purchased electricity (MWh)

6,254

Consumption of self-generated electricity (MWh)

0

Consumption of purchased heat, steam, and cooling (MWh)

0

Consumption of self-generated heat, steam, and cooling (MWh)

6,551

Total non-fuel energy consumption (MWh) [Auto-calculated]

12,805

Country/area

Costa Rica

Consumption of purchased electricity (MWh)

8,456

Consumption of self-generated electricity (MWh)

1,114

Consumption of purchased heat, steam, and cooling (MWh)

0

Consumption of self-generated heat, steam, and cooling (MWh)

3,350

Total non-fuel energy consumption (MWh) [Auto-calculated]

12,920

Country/area

United States of America

Consumption of purchased electricity (MWh)

343,103

Consumption of self-generated electricity (MWh)

0

Consumption of purchased heat, steam, and cooling (MWh)

231,727

Consumption of self-generated heat, steam, and cooling (MWh)

435,381

Total non-fuel energy consumption (MWh) [Auto-calculated]

1,010,211

Country/area

Israel

Consumption of purchased electricity (MWh)

1,800

Consumption of self-generated electricity (MWh)

0

Consumption of purchased heat, steam, and cooling (MWh)

0

Consumption of self-generated heat, steam, and cooling (MWh)
1,571

Total non-fuel energy consumption (MWh) [Auto-calculated]
3,371

Country/area
Singapore

Consumption of purchased electricity (MWh)
41,103

Consumption of self-generated electricity (MWh)
0

Consumption of purchased heat, steam, and cooling (MWh)
0

Consumption of self-generated heat, steam, and cooling (MWh)
65,786

Total non-fuel energy consumption (MWh) [Auto-calculated]
106,889

Country/area
Belgium

Consumption of purchased electricity (MWh)
729

Consumption of self-generated electricity (MWh)
0

Consumption of purchased heat, steam, and cooling (MWh)
0

Consumption of self-generated heat, steam, and cooling (MWh)
679

Total non-fuel energy consumption (MWh) [Auto-calculated]
1,408

Country/area

Germany

Consumption of purchased electricity (MWh)
15,193

Consumption of self-generated electricity (MWh)
24,357

Consumption of purchased heat, steam, and cooling (MWh)
0

Consumption of self-generated heat, steam, and cooling (MWh)
40,269

Total non-fuel energy consumption (MWh) [Auto-calculated]

79,819

Country/area
France

Consumption of purchased electricity (MWh)
10,021

Consumption of self-generated electricity (MWh)
0

Consumption of purchased heat, steam, and cooling (MWh)
0

Consumption of self-generated heat, steam, and cooling (MWh)
8,804

Total non-fuel energy consumption (MWh) [Auto-calculated]

18,825

Country/area
Ireland

Consumption of purchased electricity (MWh)
74,242

Consumption of self-generated electricity (MWh)
4,030

Consumption of purchased heat, steam, and cooling (MWh)
0

Consumption of self-generated heat, steam, and cooling (MWh)
101,744

Total non-fuel energy consumption (MWh) [Auto-calculated]

180,016

Country/area
Italy

Consumption of purchased electricity (MWh)
1,567

Consumption of self-generated electricity (MWh)
32,071

Consumption of purchased heat, steam, and cooling (MWh)
0

Consumption of self-generated heat, steam, and cooling (MWh)
26,240

Total non-fuel energy consumption (MWh) [Auto-calculated]

59,878

Country/area
Puerto Rico

Consumption of purchased electricity (MWh)
14,280

Consumption of self-generated electricity (MWh)
108,132

Consumption of purchased heat, steam, and cooling (MWh)
0

Consumption of self-generated heat, steam, and cooling (MWh)
70,984

Total non-fuel energy consumption (MWh) [Auto-calculated]

193,396

C9. Additional metrics

C9.1

(C9.1) Provide any additional climate-related metrics relevant to your business.

Description
Waste

Metric value
33,892

Metric numerator
Total Hazardous and Non-Hazardous Waste Generated

Metric denominator (intensity metric only)
Not Applicable

% change from previous year
8.1

Direction of change
Decreased

Please explain
This metric is our Absolute Total Hazardous Waste Generated (Excluding Construction and Demolition) in Metric Tons. In 2021 the value was 36,897 Metric Tons and in 2022 the value was 33892 Metric Tons (1 - 33,892 / 36,897) = 8.1% decrease

Description
Waste

Metric value
92

Metric numerator
Percent Diversion from Landfill

Metric denominator (intensity metric only)
Not Applicable

% change from previous year
0

Direction of change
No change

Please explain

This metric is the percentage of our Total Waste Generated that is diverted from landfill. In 2021 the percentage was 92% and in 2022 the percentage was again 92%.

C10. Verification

C10.1

(C10.1) Indicate the verification/assurance status that applies to your reported emissions.

	Verification/assurance status
Scope 1	Third-party verification or assurance process in place
Scope 2 (location-based or market-based)	Third-party verification or assurance process in place
Scope 3	No third-party verification or assurance

C10.1a

(C10.1a) Provide further details of the verification/assurance undertaken for your Scope 1 emissions, and attach the relevant statements.

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

2022 AbbVie Assurance Report.pdf

Page/ section reference

See page 5 for the Scope 1 Data and pages 14-15 for the assurance statement.

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

C10.1b

(C10.1b) Provide further details of the verification/assurance undertaken for your Scope 2 emissions and attach the relevant statements.

Scope 2 approach
Scope 2 location-based

Verification or assurance cycle in place
Annual process

Status in the current reporting year
Complete

Type of verification or assurance
Limited assurance

Attach the statement

2022 AbbVie Assurance Report.pdf

Page/ section reference
See page 6 for the Scope 2 Market-Based Data and pages 14-15 for the assurance statement.

Relevant standard
ISAE3000

Proportion of reported emissions verified (%)
100

Scope 2 approach
Scope 2 location-based

Verification or assurance cycle in place
Annual process

Status in the current reporting year
Complete

Type of verification or assurance
Limited assurance

Attach the statement

2022 AbbVie Assurance Report.pdf

Page/ section reference

See page 6 for the Scope 2 Location-Based Data and pages 14-15 for the assurance statement. Note that the location based data for 2022 is listed on page 6 in the text on the left side of the page and is not included in the bar chart.

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

C10.2

(C10.2) Do you verify any climate-related information reported in your CDP disclosure other than the emissions figures reported in C6.1, C6.3, and C6.5?

Yes

C10.2a

(C10.2a) Which data points within your CDP disclosure have been verified, and which verification standards were used?

2022 AbbVie Assurance Report.pdf

Disclosure module verification relates to	Data verified	Verification standard	Please explain
C8. Energy	Energy consumption	ISAE3000	See page 3 for the Total Energy Consumption Data and pages 14-15 for the assurance statement.
C9. Additional metrics	Waste data	ISAE3000	See page 9 for the Total Hazardous and Non-Hazardous Waste Data and pages 14-15 for the assurance statement.

C11. Carbon pricing

C11.1

(C11.1) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)?

Yes

C11.1a

(C11.1a) Select the carbon pricing regulation(s) which impacts your operations.

EU ETS

Ireland carbon tax

Singapore carbon tax

C11.1b

(C11.1b) Complete the following table for each of the emissions trading schemes you are regulated by.

EU ETS

% of Scope 1 emissions covered by the ETS

9.4

% of Scope 2 emissions covered by the ETS

0

Period start date

January 1, 2022

Period end date

December 31, 2022

Allowances allocated

5,118

Allowances purchased

27,219

Verified Scope 1 emissions in metric tons CO2e

32,337

Verified Scope 2 emissions in metric tons CO2e

0

Details of ownership

Facilities we own and operate

Comment

AbbVie has two facilities that are subject to the EU ETS system which are the Ludwigshaven, Germany site and the Westport, Ireland sites.

C11.1c

(C11.1c) Complete the following table for each of the tax systems you are regulated by.

Ireland carbon tax

Period start date

January 1, 2022

Period end date

December 31, 2022

% of total Scope 1 emissions covered by tax

6.6

Total cost of tax paid

971,982

Comment

The total cost of tax paid is estimated based on a current tax rate of 41 EUR per metric ton and the fuel burned (Scope 1 carbon emissions) for the six Irish sites.
22,578 Metric Tons X 41 EUR/MT X 1.05 USD/EUR = $971,983 USD

Singapore carbon tax

Period start date

January 1, 2022

Period end date

December 31, 2022

% of total Scope 1 emissions covered by tax

4.1

Total cost of tax paid

53,243

Comment

The total cost of tax paid is calculated based on a current tax rate of 5 SDG per metric ton and the fuel burned (Scope 1 emissions) for the Singapore site.
14,198 Metric Tons X 5 SGD/Mt X 0.75 USD/SGD = $53,243 USD

C11.1d

(C11.1d) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by?

Compliance with the EU ETS system is handled by the site level EHS organization at the two sites which are subject to the system. The Ludwigshaven, Germany and Westport, Ireland manufacturing sites track their emissions, track their allowances, and make decisions on purchasing or selling allowances. Both sites are audited annually for compliance with the ETS system by a third party auditing body. The AbbVie Global EHS organization also performs an internal audit to track compliance with the ETS system. The Ireland Carbon as well as the Singapore Carbon tax are paid directly within the fuel invoices, and is included in the overall cost of fuel for the manufacturing sites. Compliance with this carbon tax is handled by the various fuel vendors within their invoicing.

C11.2

(C11.2) Has your organization canceled any project-based carbon credits within the reporting year?

No

C11.3

(C11.3) Does your organization use an internal price on carbon?

No, and we do not currently anticipate doing so in the next two years

C12. Engagement

C12.1

(C12.1) Do you engage with your value chain on climate-related issues?

Yes, our suppliers

Yes, our customers/clients

C12.1a

(C12.1a) Provide details of your climate-related supplier engagement strategy.

Type of engagement

Information collection (understanding supplier behavior)

Details of engagement

Collect GHG emissions data at least annually from suppliers

Collect targets information at least annually from suppliers

% of suppliers by number

10

% total procurement spend (direct and indirect)

75

% of supplier-related Scope 3 emissions as reported in C6.5

79.1

Rationale for the coverage of your engagement

AbbVie has a validated near term 1.5 Deg C science based target which includes a supplier engagement target for Scope 3. Our Scope 3 SE target is as follows: AbbVie further commits that 79.1% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027.

We have developed a Supplier Engagement Strategy and Program to support this target. We are engaging with our top suppliers that represent 79.1% of our Scope 3 emissions. This engagement includes sending an annual supplier survey to selected top suppliers where we are collecting GHG emissions data from those suppliers. This survey also includes collecting target information.

Impact of engagement, including measures of success

To reach AbbVie's target of 79.1% of its suppliers (by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution), will have science-based targets by 2027, we would consider success as a minimum annual 9.1% increase of suppliers with SBTs from our base year until 2027, when 79.1% is reached. In our 2021 baseline year, 13.4% of AbbVie's suppliers by emissions had an approved SBT. Through our engagement with our suppliers, in 2022, this percentage increased to 23.0%. We have seen significant numbers of our suppliers also commit to the science based target initiative this past year, including our largest supplier by spend & emissions.

Comment

Type of engagement

Engagement & incentivization (changing supplier behavior)

Details of engagement

Provide training, support, and best practices on how to set science-based targets

% of suppliers by number

10

% total procurement spend (direct and indirect)

75

% of supplier-related Scope 3 emissions as reported in C6.5

79.1

Rationale for the coverage of your engagement

AbbVie has a validated near term 1.5 Deg C science based target which includes a supplier engagement target for Scope 3. Our Scope 3 SE target is as follows: AbbVie further commits that 79.1% of its suppliers by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2027.

We are engaging directly with suppliers during the course of the year on business review calls. Our purchasing category managers lead these calls with our suppliers, and they have received training on our supplier engagement target/program. Category managers are asking our suppliers if they have set a science based target or if they intend to set a science based within the next two years. We are encouraging all of our top supplier to consider setting science based targets with SBTi.

Impact of engagement, including measures of success

In our 2021 baseline year, 13.4% of AbbVie's suppliers by emissions had an approved SBT. In 2022, this percentage increased to 23.0%. We have seen significant numbers of our suppliers also commit to the science based target initiative this past year, including our largest supplier by spend & emissions.

Comment

C12.1b

(C12.1b) Give details of your climate-related engagement strategy with your customers.

Type of engagement & Details of engagement

Education/information sharing
Share information about your products and relevant certification schemes (i.e. Energy STAR)

% of customers by number

1

% of customer - related Scope 3 emissions as reported in C6.5

5

Please explain the rationale for selecting this group of customers and scope of engagement

AbbVie has participated in a number of Environmental Sustainability surveys that were requested by our customers. This includes:
Customer Environmental Sustainability Surveys
EcoVadis Survey
PSCI Environmental Survey

Customers who have requested our participation generally have been customers where we are performing third party manufacturing for the customer or customers where we are selling our products directly to the customer. AbbVie responded to surveys from 14 customers during 2022. AbbVie achieved an overall score of 70 in the EcoVadis survey (Gold Level) with a score of 70 in the Environment section and a score of 60 in the sustainable procurement section. AbbVie completed two PSCI Environmental surveys for customers during 2022.

AbbVie has also shared that we have achieved the following certifications:
Twelve of our global sites are ISO50001 certified as of 2022
Three of our U.S. based site are EnergySTAR certified in 2022
AbbVie was selected as an EnergySTAR partner of the year for 2022

Impact of engagement, including measures of success

Success could be measured or based on a threshold of continued customer relationships/customer retention after responding to surveys. As an example, the customers that requested AbbVie to participate in the various surveys, have continued their relationship with AbbVie after our participation. We view this a positive and impactful engagement strategy.

C12.2

(C12.2) Do your suppliers have to meet climate-related requirements as part of your organization's purchasing process?

No, and we do not plan to introduce climate-related requirements within the next two years

C12.3

(C12.3) Does your organization engage in activities that could either directly or indirectly influence policy, law, or regulation that may impact the climate?

Row 1

External engagement activities that could directly or indirectly influence policy, law, or regulation that may impact the climate

Not assessed

Does your organization have a public commitment or position statement to conduct your engagement activities in line with the goals of the Paris Agreement?

No, and we do not plan to have one in the next two years

Describe the process(es) your organization has in place to ensure that your external engagement activities are consistent with your climate commitments and/or climate transition plan

Our climate change strategy is established and communicated as our Corporate Energy Policy. Our policy states that we will take steps to reduce carbon emissions through the efficient use of energy in developing and delivering our products, as well as engaging where there is the opportunity to influence or impact our use, procurement or conservation of energy. AbbVie does not have a documented public commitment for our engagement activities to ensure that they are in line with the goals of the Paris Agreement. However, in 2021, we enhanced our ESG oversight and governance with the establishment of an ESG Council. The ESG Council ensures strategic, enterprise-aligned delivery on AbbVie's ESG Framework. Chaired by our Vice Chairman, External Affairs and Chief Legal Officer and composed of senior cross functional leaders, the ESG Council's purpose is to champion business sustainability and mitigate business risks by monitoring, reviewing and recommending actions in support of our ESG framework and strategy. The ESG Council meets at minimum once per quarter and maintains sub-committees aligned to AbbVie's material topics which included Environmental Sustainability. This council would have oversight and decision making ability in a situation where engagement with a trade associate may not align with the goals of the Paris Agreement.

C12.4

(C12.4) Have you published information about your organization's response to climate change and GHG emissions performance for this reporting year in places other than in your CDP response? If so, please attach the publication(s).

Publication
In mainstream reports

Status
Complete

Attach the document
2022 ESG Report.pdf

Page/Section reference
Environmental Section Pages 14-23

Content elements
Governance
Strategy
Risks & opportunities
Emissions figures
Emission targets
Other metrics

Comment
In May 2023, AbbVie published our annual ESG report. This report is publicly available on abbvie.com.

Publication
In mainstream reports, incorporating the TCFD recommendations

Status
Complete

Attach the document
AbbVie 2023 TCFD Update.pdf

Page/Section reference
Pages 1-4

Content elements
Governance

Strategy
Risks & opportunities
Emission targets

Comment

In 2022, AbbVie published our initial TCFD report, and this report was updated in early 2023. This report is publicly available on abbvie.com.

C12.5

(C12.5) Indicate the collaborative frameworks, initiatives and/or commitments related to environmental issues for which you are a signatory/member.

	Environmental collaborative framework, initiative and/or commitment	Describe your organization's role within each framework, initiative and/or commitment
Row 1	Science Based Targets Network (SBTN) Task Force on Climate-related Financial Disclosures (TCFD) UN Global Compact Other, please specify	In 2022, AbbVie published our initial TCFD report which is aligned to the TCFD framework, and this report was updated in early 2023. This report is publicly available on abbvie.com. In 2022, AbbVie submitted our near term 1.5 C Science Based Targets for validation to SBTi. These targets were validated in early 2023. AbbVie reported our progress in our annual 2022 ESG report for these targets in alignment with our commitment to SBTi. AbbVie submitted our application for the UN Global Compact in late 2022. The application acceptance process currently in-process. AbbVie is an active member of the Pharmaceutical Environmental Group (PEG) which is a collaborative of the top 19 Pharmaceutical Companies. This group works together to improve the environmental sustainability and performance of the world's leading Pharmaceutical Companies. AbbVie has representation on all five of the PEG working groups including the working group focused on climate change.

C15. Biodiversity

C15.1

(C15.1) Is there board-level oversight and/or executive management-level responsibility for biodiversity-related issues within your organization?

	Board-level oversight and/or executive management-level responsibility for biodiversity-related issues

Row 1	No, and we do not plan to have both within the next two years

C15.2

(C15.2) Has your organization made a public commitment and/or endorsed any initiatives related to biodiversity?

	Indicate whether your organization made a public commitment or endorsed any initiatives related to biodiversity
Row 1	No, and we do not plan to do so within the next 2 years

C15.3

(C15.3) Does your organization assess the impacts and dependencies of its value chain on biodiversity?

Impacts on biodiversity

Indicate whether your organization undertakes this type of assessment

No, but we plan to within the next two years

Dependencies on biodiversity

Indicate whether your organization undertakes this type of assessment

No, but we plan to within the next two years

C15.4

(C15.4) Does your organization have activities located in or near to biodiversity-sensitive areas in the reporting year?

Yes

C15.4a

(C15.4a) Provide details of your organization's activities in the reporting year located in or near to biodiversity -sensitive areas.

Classification of biodiversity -sensitive area

Key Biodiversity Area (KBAs)

Country/area

United States of America

Name of the biodiversity-sensitive area

Detroit River

Proximity

Adjacent

Briefly describe your organization's activities in the reporting year located in or near to the selected area

AbbVie operates a facility where we produce active pharmaceutical ingredients in Wyandotte, Michigan which is adjacent to the Detroit River. The river is designated a Key Biodiversity Area by the Key Biodiversity Area Partnership. This was determined using the KBA online mapping tool at www.keybiodiversityareas.org.

Indicate whether any of your organization's activities located in or near to the selected area could negatively affect biodiversity

Yes, but mitigation measures have been implemented

Mitigation measures implemented within the selected area

Physical controls

Operational controls

Explain how your organization's activities located in or near to the selected area could negatively affect biodiversity, how this was assessed, and describe any mitigation measures implemented

This facility has a strong environmental management system in place, and the facility is ISO 14001 certified for Environmental Management. The site's environmental management system is designed to mitigate any negative impact from our operations on this natural resource. Physical and Operational controls are in place to manage water and air impacts.

C15.5

(C15.5) What actions has your organization taken in the reporting year to progress your biodiversity-related commitments?

	Have you taken any actions in the reporting period to progress your biodiversity-related commitments?	Type of action taken to progress biodiversity- related commitments
Row 1	Yes, we are taking actions to progress our biodiversity-related commitments	Land/water protection

C15.6

(C15.6) Does your organization use biodiversity indicators to monitor performance across its activities?

	Does your organization use indicators to monitor biodiversity performance?	Indicators used to monitor biodiversity performance
Row 1	No, we do not use indicators, but plan to within the next two years	

C15.7

(C15.7) Have you published information about your organization's response to biodiversity-related issues for this reporting year in places other than in your CDP response? If so, please attach the publication(s).

Report type	Content elements	Attach the document and indicate where in the document the relevant biodiversity information is located
In voluntary sustainability report or other voluntary communications	Impacts on biodiversity	See Page 23 of the AbbVie 2022 ESG Report for a section on Biodiversity impacts. [1]

[1] 2022 ESG Report.pdf

C16. Signoff

C-FI

(C-FI) Use this field to provide any additional information or context that you feel is relevant to your organization's response. Please note that this field is optional and is not scored.

Not Applicable.

C16.1

(C16.1) Provide details for the person that has signed off (approved) your CDP climate change response.

	Job title	Corresponding job category
Row 1	Head of Global EHS	Other, please specify Global Environment, Health, and Safety Vice President

Submit your response

In which language are you submitting your response?

English

Please confirm how your response should be handled by CDP

	I understand that my response will be shared with all requesting stakeholders	Response permission
Please select your submission options	Yes	Public